VerifyMe (VRME) S-1/A 9 Dec 19 IPO registration (amended) Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Sep. 30, 2019
Document And Entity Information
Entity Registrant Name	VerifyMe, Inc.
Entity Central Index Key	0001104038
Document Type	S-1/A
Document Period End Date	Sep. 30, 2019
Amendment Flag	true
Amendment Description	CALCULATION OF REGISTRATION FEE Title of each class of securities to be registered (1) Proposed Maximum Aggregate Offering Price Amount of Registration Fee Units consisting of shares of Common Stock, par value $0.001 per share, and Warrants to purchase shares of Common Stock, par value $0.001 per share (2) $ 9,200,000 $ 1,194 (8) Common Stock included as part of the Units — — Warrants to purchase shares of Common Stock included as part of the Units (3) — — Shares of Common Stock issuable upon exercise of the Warrants (4)(5) $ — $ Representative’s Warrants (5) — — Shares of Common Stock issuable upon exercise of Representative’s Warrants (6)(7) $ 704,000 $ 92 (8) Total $ 9,904,000 $ 1,286 (8) (1) In the event of a stock split, stock dividend, or similar transaction involving our common stock, the number of shares registered shall automatically be increased to cover the additional shares of common stock issuable pursuant to Rule 416 under the Securities Act. (2) Includes stock and/or warrants that may be issued upon exercise of a 45-day option granted to the representative of the underwriters to cover over-allotments, if any. (3) In accordance with Rule 457(i) under the Securities Act, because the shares of the Registrant’s common stock underlying the warrants and Representative’s warrants are registered hereby, no separate registration fee is required with respect to the warrants registered hereby. (4) There will be issued warrants to purchase shares of common stock for every shares of common stock offered. The warrants are exercisable at a per share price of % of the common stock public offering price. (5) No additional registration fee is payable pursuant to Rule 457(g) under the Securities Act. (6) Includes shares of common stock which may be issued upon exercise of additional warrants which may be issued upon exercise of 45-day option granted to the representative of the underwriters to cover over-allotments, if any. (7) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act. The warrants are exercisable at a per share exercise price equal to 110% of the public offering price. As estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under the Securities Act, the proposed maximum aggregate offering price of the Representative’s warrants is $704,000, which is equal to 110% of $640,000 (8% of $8,000,000). (8) Previously paid. The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.
Entity Incorporation, State or Country Code	NY
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false

Balance Sheets (Unaudited)

Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
CURRENT ASSETS
Cash and cash equivalents	$ 671,011	$ 1,673,201	$ 693,001
Accounts Receivable	51,415	30,373
Deposits on Equipment	163,090
Prepaid expenses and other current assets	29,981	25,781	18,668
Inventory	37,962	41,982
TOTAL CURRENT ASSETS	953,459	1,771,337	711,669
INTANGIBLE ASSETS
Patents and Trademarks, net of accumulated amortization of $275,591 and $258,294 as of September 30, 2019 and December 31, 2018	228,705	209,049	191,507
Capitalized Software Costs	141,656	70,231
TOTAL ASSETS	1,323,820	2,050,617	903,176
CURRENT LIABILITIES
Convertible Debt, net of unamortized debt discount	228,478
Derivative Liability	207,534
Accounts payable and other accrued expenses	354,766	411,211	923,202
Notes payable			50,000
Common Stock payable			122,478
Accrued Payroll	106,438	69,041
TOTAL CURRENT LIABILITIES	897,216	480,252	1,095,680
STOCKHOLDERS' EQUITY
Common stock of $.001 par value; 675,000,000 authorized; 111,252,373 and 102,553,706 issued, 110,901,833 and 102,203,166 shares outstanding as of September 30, 2019 and December 31, 2018	110,902	102,203	53,522
Additional paid in capital	61,578,151	60,844,796	56,198,126
Treasury stock as cost (350,540 shares at September 30, 2019 and December 31, 2018)	(113,389)	(113,389)	(113,389)
Accumulated deficit	(61,149,060)	(59,263,550)	(56,331,088)
STOCKHOLDERS' EQUITY	426,604	1,570,365	(192,504)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	1,323,820	2,050,617	903,176
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY
Convertible Preferred Stock		305	325
STOCKHOLDERS' EQUITY		305	325
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY
Convertible Preferred Stock
STOCKHOLDERS' EQUITY

Balance Sheets (Unaudited) (Par

Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Accumulated amortization, patent and trademarks	$ 275,591	$ 258,294	$ 237,331
Common stock, par value	$ 0.001	$ 0.001	$ 0.001
Common stock, shares authorized	675,000,000	675,000,000	675,000,000
Common stock, shares issued	111,252,373	102,553,706	53,873,872
Common stock, shares outstanding	110,901,833	102,203,166	53,523,332
Treasury stock, shares	350,540	350,540	350,540
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	37,564,767	37,564,767	37,564,767
Preferred stock, shares issued	0	304,778	324,778
Preferred stock, shares outstanding	0	304,778	324,778
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001	$ 0.001
Preferred stock, shares authorized	85	85	85
Preferred stock, shares issued	0.85	0.85	0.92
Preferred stock, shares outstanding	0.85	0.85	0.92

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended				9 Months Ended				12 Months Ended
	Sep. 30, 2019		Sep. 30, 2018		Sep. 30, 2019		Sep. 30, 2018		Dec. 31, 2018		Dec. 31, 2017
NET REVENUE
Sales	$ 56,225		$ 28,273		$ 143,158		$ 35,072		$ 74,884
COST OF SALES	8,471		12,281		30,323		14,281		28,802
GROSS PROFIT	47,754		15,992		112,835		20,791		46,082
OPERATING EXPENSES
General and administrative	350,851	[1]	357,665	[1]	1,001,728	[1]	1,378,999	[1]	1,585,329	[2]	1,689,883	[2]
Legal and accounting	41,977		64,897		172,676		362,371		416,772		246,520
Payroll expenses	167,807	[1]	77,664	[1]	374,382	[1]	269,518	[1]	316,837	[2]	767,257	[2]
Research and development	804		73,843		7,055		102,272		187,655		128,044
Sales and marketing	148,416	[1]	9,150	[1]	400,717	[1]	17,217	[1]	135,290		3,800
Total Operating expenses	709,855		583,219		1,956,558		2,130,377		2,641,883		2,835,504
LOSS BEFORE OTHER INCOME (EXPENSE)	(662,101)		(567,227)		(1,843,723)		(2,109,586)		(2,595,801)		(2,835,504)
OTHER (EXPENSE) INCOME
Interest income (expenses), net	(8,338)		1,084		(5,678)		1,367		6,664		(218,316)
Change in fair value of embedded derivative	(36,109)				(36,109)
Gain on derecognition of note payable and accrued interest			86,667				86,667		83,667
Settlement agreement with shareholders							(779,000)		(779,000)
Gain on accounts payable forgiveness							402,248		352,008
Loss on settlement of related party notes payable											(331,912)
Other income											392
TOTAL OTHER INCOME (EXPENSE)	(44,447)		87,751		(41,787)		(288,718)		(336,661)		(549,836)
NET LOSS	$ (706,548)		$ (479,476)		$ (1,885,510)		$ (2,398,304)		(2,932,462)		(3,385,340)
Less: Deemed dividend on convertible preferred shares											(596,878)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS									$ (2,932,462)		$ (3,982,218)
LOSS PER SHARE
BASIC (in dollars per share)	$ (0.01)		$ 0		$ (0.02)		$ (0.03)		$ (0.03)		$ (0.14)
DILUTED (in dollars per share)	$ (0.01)		$ 0		$ (0.02)		$ (0.03)		$ (0.03)		$ (0.14)
WEIGHTED AVERAGE COMMON SHARE OUTSTANDING
BASIC (in shares)	98,137,735		101,186,416		98,209,139		91,453,702		93,851,170		28,244,361
DILUTED (in shares)	98,137,735		101,186,416		98,209,139		91,453,702		93,851,170		28,244,361
[1]	Includes share-based compensation of $322,641 and $671,649 for the three and nine months ended September 30, 2019 and $204,227 and $709,940 for the three and nine months ended September 30, 2018.
[2]	Includes share-based compensation of $828,203 and $1,800,181 for the years ended December 31, 2018 and 2017, respectively.

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (1,885,510)	$ (2,398,304)	$ (2,932,462)	$ (3,385,340)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	103,167	44,120	44,120	139,808
Fair value of options and warrants issued in exchange for services	399,828	270,339	329,193	1,295,741
Fair value of restricted stock and restricted stock units issued in exchange for services	168,654	395,481	454,890	66,825
Common stock and warrants issued for services				297,807
Gain on accounts payable forgiveness		(402,248)	(352,008)
Share-based payment for settlement agreement with shareholders		279,000	279,000
Gain on derecognition of note payable and accrued interest		(86,667)	(83,667)
Amortization of debt discount	8,696			174,517
Change in Fair Value of Embedded Derivative	36,109
Interest rolled into principal				30,000
Loss on conversion of related party notes payable and accrued interest				331,912
Amortization and depreciation	17,297	15,928	20,963	43,095
Changes in operating assets and liabilities:
Accounts Receivable	(21,042)	(28,462)	(30,373)
Deposit on Equipment	(163,090)
Inventory	4,020	(35,102)	(41,982)	17,093
Prepaid expenses and other current assets	(4,200)		(7,113)	(9,243)
Accounts payable and accrued expenses	(19,048)	(41,550)	(57,275)	61,867
Net cash used in operating activities	(1,355,119)	(1,987,465)	(2,376,714)	(935,918)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of Patents	(36,953)	(16,690)	(38,505)	(2,650)
Capitalized Software Costs	(71,425)	(30,223)	(70,231)
Net cash used in investing activities	(108,378)	(46,913)	(108,736)	(2,650)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from convertible debt, net of costs	461,307
Proceeds from exercise of warrants		2,311,438	2,312,005
Proceeds from issuance of related party notes payable				281,000
Proceeds from sale of common stock		1,154,211	1,153,645	1,327,925
Net cash provided by financing activities	461,307	3,465,649	3,465,650	1,608,925
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(1,002,190)	1,431,271	980,200	670,357
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD	1,673,201	693,001	693,001	22,644
CASH AND CASH EQUIVALENTS - END OF PERIOD	671,011	2,124,272	1,673,201	693,001
Cash paid during the period for:
Interest
Income taxes
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Cumulative effect of adoption of ASU 2017-11				623,462
Common Stock issued in relation to convertible debt	70,100
Recognition of embedded derivative liability	171,425
Cashless Exercise of Stock Options		4,028
Cashless Exercise of Warrants	72	176
Cashless Exercise of Stock Options			4,028
Cashless Exercise of Warrants			183
Common Stock and Warrants Issued for Common Stock Payable		122,478	122,478
Deemed divided distribution on issuance of common stock for conversion of Series C and Series D				596,878
Warrants issued as discount to notes payable				113,586
Conversion of related party notes payable and accrued interest into common stock				273,623
Common stock payable for conversion of related party notes payable and accrued interest				122,478
Sale of common stock - past issuances				503
Series A Convertible Preferred Stock [Member]
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Convertible Preferred Stock converted to common stock			400	1,460
Series B Convertible Preferred Stock [Member]
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Convertible Preferred Stock converted to common stock			599
Series C Convertible Preferred Stock [Member]
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Convertible Preferred Stock converted to common stock				4,768
Warrants into common stock				6,175
Series D Convertible Preferred Stock [Member]
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Convertible Preferred Stock converted to common stock				496
Warrants into common stock				$ 1,986
Series A Convertible Preferred Stock [Member]
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Convertible Preferred Stock converted to common stock	6,096	400
Series B Convertible Preferred Stock [Member]
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES
Convertible Preferred Stock converted to common stock		$ 599

Statement of Stockholders' Equi

Statement of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Series A Convertible Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Series C Convertible Preferred Stock [Member]	Series D Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Treasury Stock [Member]	Accumulated Deficit [Member]	Total
Balance at beginning at Dec. 31, 2016	$ 398		$ 1,913	$ 167	$ 8,331	$ 40,469,272	$ (113,389)	$ (41,644,545)	$ (1,277,853)
Balance at beginning (in shares) at Dec. 31, 2016	397,778	0.92	1,912,500	166,750	8,330,696
Cumulative adjustment related to change in accounting principle (Note 1, Change in Accounting Principle) at Dec. 31, 2016						11,924,665		(11,301,203)	623,462
Adjusted balance at beginning at Dec. 31, 2016	$ 398		$ 1,913	$ 167	$ 8,331	52,393,937	(113,389)	(52,945,748)	(654,391)
Adjusted balance at beginning (in shares) at Dec. 31, 2016	397,778	0.92	1,912,500	166,750	8,330,696
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of Series A Convertible Preferred Stock	$ (73)				$ 1,460	(1,387)
Conversion of Series A Convertible Preferred Stock (in shares)	(73,000)				1,460,000
Conversion Preferred C - Warrants					$ 6,175	(6,175)
Conversion Preferred C - Warrants (in shares)					6,175,000
Conversion of Series B Convertible Preferred Stock (in shares)	1,460,000
Conversion of Series C Convertible Preferred Stock			$ (1,913)		$ 4,768	(2,855)
Conversion of Series C Convertible Preferred Stock (in shares)			(1,912,500)		4,767,858
Conversion of Series D Convertible Preferred Stock				$ (166,750)	$ 496	(329)
Conversion of Series D Convertible Preferred Stock (in shares)				(167)	496,429
Conversion Preferred D - Warrants					$ 1,986	(1,986)
Conversion Preferred D - Warrants (in shares)					1,985,716
Sale of common stock					$ 19,452	1,340,798			$ 1,360,250
Sale of common stock (in shares)					19,451,575				120,000
Sale of common stock - Past issuances					$ 503	(503)
Sale of common stock - Past issuances (in shares)					503,432
Stock Based Compensation					$ 2,050	137,758			$ 139,808
Stock Based Compensation (in shares)					2,050,372				2,050,372
Stock issuance costs						(32,325)			$ (32,325)
Conversion of related party notes payable and accrued interest into common stock					$ 4,402	601,133			605,535
Conversion of related party notes payable and accrued interest into common stock (in shares)					4,402,079
Discount on warrants issued in conjunction with related party notes payable						113,586			113,586
Common stock and warrants issued for services					$ 1,724	296,083			297,807
Common stock and warrants issued for services (in shares)					1,725,175
Fair value of stock option						1,295,741			1,295,741
Restricted Stock awards					$ 2,175	64,650			66,825
Restricted Stock awards (in shares)					2,175,000
Deemed dividend distribution on issuance of common stock for conversion of Series C and Series D						(596,878)			(596,878)
Accretion of deemed dividend distribution on issuance of common stock for conversion of Series C and Series D						596,878			596,878
Net loss								(3,385,340)	(3,385,340)
Balance at ending at Dec. 31, 2017	$ 325				$ 53,522	56,198,126	(113,389)	(56,331,088)	(192,504)
Balance at ending (in shares) at Dec. 31, 2017	324,778	0.92			53,523,332
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of Series A Convertible Preferred Stock	$ (20)				$ 400	(380)
Conversion of Series A Convertible Preferred Stock (in shares)	(20,000)				400,000
Conversion of Series B Convertible Preferred Stock					$ 599	(599)
Conversion of Series B Convertible Preferred Stock (in shares)		(0.07)			599,362
Sale of common stock					$ 15,906	1,138,305			1,154,211
Sale of common stock (in shares)					15,906,168
Settlement Agreement					$ 1,000	278,000			279,000
Settlement Agreement (in shares)					1,000,000
Conversion of notes payable					$ 1,750	120,728			122,478
Conversion of notes payable (in shares)					1,749,683
Exercise of Warrants					$ 22,608	2,288,830			2,311,438
Exercise of Warrants (in shares)					22,607,845
Common stock and warrants issued for services					$ 170	43,950			44,120
Common stock and warrants issued for services (in shares)					169,500
Cashless Exercise of Stock Options					$ 4,028	(4,028)
Cashless Exercise of Stock Options (in shares)					4,027,778
Fair value of stock option						270,339			270,339
Restricted Stock awards (in shares)					2,212,500
Restricted Stock awards and Restricted Stock Units					$ 2,213	393,268			395,481
Restricted Stock awards and Restricted Stock Units (in shares)					2,212,500
Net loss								(2,398,304)	(2,398,304)
Balance at ending at Sep. 30, 2018	$ 305				$ 102,196	60,726,539	(113,389)	(58,729,392)	1,986,259
Balance at ending (in shares) at Sep. 30, 2018	304,778	0.85			102,196,168
Balance at beginning at Dec. 31, 2017	$ 325				$ 53,522	56,198,126	(113,389)	(56,331,088)	(192,504)
Balance at beginning (in shares) at Dec. 31, 2017	324,778	0.92			53,523,332
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of Series A Convertible Preferred Stock	$ (20)				$ 400	(380)
Conversion of Series A Convertible Preferred Stock (in shares)	20,000				400,000
Conversion of Series B Convertible Preferred Stock					$ 599	(599)
Conversion of Series B Convertible Preferred Stock (in shares)	400,000	(0.07)			599,362
Sale of common stock					$ 15,906	1,137,739			$ 1,153,645
Sale of common stock (in shares)					15,906,168				16,513,311
Settlement Agreement					$ 1,000	278,000			$ 279,000
Settlement Agreement (in shares)					1,000,000
Conversion of notes payable					$ 1,750	120,728			122,478
Conversion of notes payable (in shares)					1,749,683
Common stock issued for services					$ 170	43,950			44,120
Common stock issued for services (in shares)					169,500
Cash Exercise of Warrants					$ 22,432	2,289,573			2,312,005
Cash Exercise of Warrants (in shares)					22,432,184
Cashless Exercise of Warrants					$ 183	(183)
Cashless Exercise of Warrants (in shares)					182,659
Cashless Exercise of Stock Options					$ 4,028	(4,028)
Cashless Exercise of Stock Options (in shares)					4,027,778
Fair value of stock option						329,193			329,193
Restricted Stock awards and Restricted Stock Units					$ 2,213	452,677			454,890
Restricted Stock awards and Restricted Stock Units (in shares)					2,212,500
Net loss								(2,932,462)	(2,932,462)
Balance at ending at Dec. 31, 2018	$ 305				$ 102,203	60,844,796	(113,389)	(59,263,550)	1,570,365
Balance at ending (in shares) at Dec. 31, 2018	304,778	0.85			102,203,166
Balance at beginning at Jun. 30, 2018	$ 305				$ 101,165	60,305,122	(113,389)	(58,249,916)	2,043,287
Balance at beginning (in shares) at Jun. 30, 2018	304,778	0.85			101,165,202
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Sale of common stock					$ (607)	607
Sale of common stock (in shares)					(607,143)
Exercise of Warrants					$ 1,638	216,583			218,221
Exercise of Warrants (in shares)					1,638,109
Fair value of stock option						44,151			44,151
Restricted Stock awards and Restricted Stock Units						160,076			160,076
Restricted Stock awards and Restricted Stock Units (in shares)
Net loss								(479,476)	(479,476)
Balance at ending at Sep. 30, 2018	$ 305				$ 102,196	60,726,539	(113,389)	(58,729,392)	1,986,259
Balance at ending (in shares) at Sep. 30, 2018	304,778	0.85			102,196,168
Balance at beginning at Dec. 31, 2018	$ 305				$ 102,203	60,844,796	(113,389)	(59,263,550)	1,570,365
Balance at beginning (in shares) at Dec. 31, 2018	304,778	0.85			102,203,166
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of Series A Convertible Preferred Stock	$ (305)				$ 6,096	(5,791)
Conversion of Series A Convertible Preferred Stock (in shares)	(304,778)				6,095,569
Common stock issued for services					$ 771	102,396			103,167
Common stock issued for services (in shares)					771,324
Common stock issued in relation to Bridge Financing					$ 1,000	69,100			70,100
Common stock issued in relation to Bridge Financing (in shares)					1,000,000
Cashless Exercise of Warrants					$ 72	(72)
Cashless Exercise of Warrants (in shares)					71,774
Fair value of stock option						399,828			399,828
Restricted Stock awards and Restricted Stock Units					$ 760	167,894			168,654
Restricted Stock awards and Restricted Stock Units (in shares)					760,000
Net loss								(1,885,510)	(1,885,510)
Balance at ending at Sep. 30, 2019					$ 110,902	61,578,151	(113,389)	(61,149,060)	426,604
Balance at ending (in shares) at Sep. 30, 2019		0.85			110,901,833
Balance at beginning at Jun. 30, 2019					$ 109,322	61,186,990	(113,389)	(60,442,512)	740,411
Balance at beginning (in shares) at Jun. 30, 2019		0.85			109,321,833
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common stock issued for services					$ 700	87,467			88,167
Common stock issued for services (in shares)					700,000
Common stock issued in relation to Bridge Financing					$ 1,000	69,100			70,100
Common stock issued in relation to Bridge Financing (in shares)					1,000,000
Fair value of stock option						150,040			150,040
Restricted Stock awards and Restricted Stock Units					$ (120)	84,554			84,434
Restricted Stock awards and Restricted Stock Units (in shares)					(120,000)
Net loss								(706,548)	(706,548)
Balance at ending at Sep. 30, 2019					$ 110,902	$ 61,578,151	$ (113,389)	$ (61,149,060)	$ 426,604
Balance at ending (in shares) at Sep. 30, 2019		0.85			110,901,833

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of the Business The Company was incorporated in the State of Nevada on November 10, 1999. The Company is based in Rochester, New York and its common stock, par value $0.001 per share, is traded on the over-the-counter market and quoted on the OTCQB. The Company is a developmental stage technology solutions provider specializing in brand protection functions such as counterfeit prevention, authentication, serialization, track and trace features for labels, packaging and products. Leveraging our covert luminescent pigment, RainbowSecure®, which we began commercializing in 2018, we also developed the patent pending VeriPAS™ software system in 2018, which covertly and overtly serializes products to track a product’s “life cycle” for brand owners. VeriPAS™ is capable of fluorescing, decoding, and verifying invisible RainbowSecure® codes in the field – designed to allow investigators to quickly and efficiently authenticate product throughout the distribution chain, including warehouses, ports of entry, retail locations, and product purchased over the internet for inspection and investigative actions. This technology is coupled with a secure cloud based track and trace software engine which allows brands and investigators to see where products originate and where they are deployed with geo location mapping and intelligent programable alerts. Brand owners access the VeriPAS™ software over the internet. Brand owners can then set rules of engagement, establish marketing programs for customer engagement and control, and monitor and protect their products “life cycle.” We have not yet derived any revenue from our VeriPAS™ software system and have derived minimal revenue from the sale of our RainbowSecure® technology. The accompanying unaudited interim financial statements (the “Interim Statements”) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by U. S. generally accepted accounting principles (“GAAP”) for complete financial statements are not included herein. The Interim Statements should be read in conjunction with the financial statements and notes thereto included in the Company’s latest Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2019. The accompanying Interim Statements are unaudited; however, in the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The interim results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019 or for any future interim periods. The Company’s activities are subject to significant risks and uncertainties, including the need to secure additional funding for working capital and to further develop the Company’s intellectual property. Basis of Presentation The accompanying financial statements are presented in accordance with GAAP. Revenue Recognition The Company accounts for revenues according to Accounting Standards Codification (“ASC”) Topic 606, “ Revenue from Contracts with Customers” The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements: · identify the contract with a customer; · identify the performance obligations in the contract; · determine the transaction price; · allocate the transaction price to performance obligations in the contract; and · recognize revenue as the performance obligations are satisfied. During the three and nine months ended September 30, 2019, the Company’s revenues consisted of revenue primarily generated from customer’s printing labels utilizing the Company’s technology. Equity-linked Financial Instruments Certain of the Company’s debt instruments include embedded derivatives that require bifurcation from the host contract under the provisions of ASC 815, Derivatives and Hedging. Under this guidance, the Company recognizes the embedded derivatives at fair value and records a gain or loss resulting from the change in fair values at the end of each reporting period. In connection with issuance of the Debentures, described in Note 4 – Convertible Debt, after March 17, 2020, the Company could become contingently obligated to issue shares potentially in excess of its authorized share limit. Consequently, the ability to settle these obligations with shares would be unavailable causing these and other share-settled obligations to potentially be settled in cash. The Company applies a sequencing policy regarding share settlement wherein equity-linked financial instruments with the earliest issuance date would be settled first. Thus, all equity-linked financial instruments, which are convertible or exercisable into common stock, issued concurrent or subsequent to the Debentures are classified as derivative liabilities, with the exception of instruments related to employee share-based compensation. Sequencing As of September 19, 2019, the Company adopted a sequencing policy whereby all equity-linked instruments issued prior to the closing of the $600,000 secured Convertible Debentures on September 19, 2019 may be classified as equity and all future equity-linked instruments may be classified as a derivative liability with the exception of instruments related to share-based compensation issued to employees or directors. Basic and Diluted Net Income per Share of Common Stock The Company follows FASB ASC 260, “Earnings Per Share,” when reporting earnings per share resulting in the presentation of basic and diluted earnings per share. Because the Company reported a net loss for each of the periods presented, common stock equivalents, including preferred stock, stock options and warrants were anti-dilutive; therefore, the amounts reported for basic and diluted loss per share were the same. For each of the three and nine months ended September 30, 2019 and 2018, there were shares potentially issuable, that could dilute basic earnings per share in the future that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive to the Company’s losses during the years presented. For each of the three and nine months ended September 30, 2019, there were approximately 56,699,000 anti-dilutive shares consisting of 20,114,000 shares issuable upon exercise of options, 21,963,000 shares issuable upon exercise of warrants, 7,222,000 shares issuable upon conversion of preferred stock and 4,000,000 shares issuable upon conversion of convertible debentures. For the three and nine months ended September 30, 2018, there were approximately 41,237,000 anti-dilutive shares consisting of 18,014,000 shares issuable upon exercise of options, 9,909,000 shares issuable upon exercise of warrants and 13,314,000 shares issuable upon conversion of preferred stock. Going Concern The Company has suffered recurring losses from operations and negative cash flows from operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. In order to continue as a going concern, develop a reliable source of revenues, and achieve a profitable level of operations the Company will need, among other things, additional capital resources. Management's plans to continue as a going concern include raising additional capital through increased sales of product and raising additional capital through incurrence of debt and the sale of our common stock and other equity securities. On September 19, 2019, the Company received net proceeds of $461,307 from the Bridge Financing, described below in Note 4 – Convertible Debt. The Company’s business plans are dependent on the ability to raise capital through private placements of our common stock and/or preferred stock, through the possible exercise of outstanding options and warrants, through debt financing and/or through the future public offerings of our securities. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. As a result of the Bridge Financing, the Company’s existing cash resources are sufficient to sustain our operations through December 2019. The Company needs to raise additional funds in the future in order to remain operational past that date. Recently Adopted Accounting Pronouncements Effective January 1, 2019, the Company adopted ASU No. 2018-07, Compensation – Stock Based Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”), which aligns accounting for share-based payments issued to nonemployees to that of employees under the existing guidance of Topic 718, with certain exceptions. This update supersedes previous guidance for equity-based payments to nonemployees under Subtopic 505-50, Equity – Equity-Based Payments to Non-Employees. The adoption of ASU 2018-07 did not have a material impact on the Company’s financial statements. Effective January 1, 2019, the Company adopted ASU No. 2016-02 – “Lease (Topic 842)” and the series of related Accounting Standards Updates that followed (collectively referred to as “Topic 842”) using the modified retrospective approach. The adoption of Topic 842 did not have a material impact on the Company’s financial statements.	NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Nature of Business The Company was incorporated in the State of Nevada on November 10, 1999. The Company is based in Rochester, New York and its common stock, par value $0.001 per share, is traded on the over-the-counter market and quoted on the OTCQB. The Company is a technology pioneer in the anti-counterfeiting industry. This broad market encompasses counterfeiting of physical and material goods and products, as well as counterfeiting of identity in digital transactions. The Company is able to deliver security solutions for identification and authentication of people, products and packaging in a variety of applications in the security field for physical transactions and owns digital patents which are in the same field. The products can be used to manage and issue secure credentials, including national IDs, passports, driver licenses and access control credentials, as well as comprehensive authentication security software to secure physical and logical access to facilities, computer networks, internet sites and mobile applications. The Company’s activities are subject to significant risks and uncertainties, including the need to secure additional funding to further develop the Company’s patents. Basis of Presentation The accompanying financial statements are presented in accordance with accounting principles generally accepted in the United States of America. Change in Accounting Principle In July 2017, the FASB issued ASU 2017-11. Part I relates to the accounting for certain financial instruments with down round features in Subtopic 815-40, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced based on the pricing of future equity offerings. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. In the case where the exception from derivative accounting does not apply, warrants must be accounted for as a liability and recorded at fair value at the date of grant and re-valued at the end of each reporting period. The Company’s warrants and embedded conversion feature on its preferred stock (see Notes 6 and 7) include anti-dilution provisions characterized as down round features and have previously been accounted for as liabilities, with the fair value of the liabilities remeasured at each reporting date and the change in liabilities recorded as other non-operating income or loss. The Company had recorded a “Warrant liability” and “Embedded derivative liability” of $623,462, in the aggregate, and gain on the change in fair value of warrants and embedded derivative liability of $11,301,203, in the aggregate, in its “Accumulated deficit” as reported in its Balance Sheets for the year ended December 31, 2016 relating to the warrant liability and embedded derivative liability. The following table details the approximate fair value measurements within the fair value hierarchy of the Company’s derivative liabilities using Level 3 inputs: Total Balance, January 1, 2016 $ 1,802,375 Series C embedded derivative fair value, February 2016 1,235,000 Effect of conversion of Series C Preferred Stock on embedded derivative liability (350,500 ) Series C warrant liability fair value, February 2016 1,767,576 Series D embedded derivative fair value, October 2016 42,521 Series D warrant liability fair value, October 2016 181,942 Change in fair value of derivative liabilities (4,055,452 ) Balance, December 31, 2016 623,462 Cumulative adjustments related to change in accounting principle, January 1, 2017 (623,462 ) Balance, December 31, 2017 $ — Except for the down round features in the warrants and embedded conversion feature, the warrants and embedded conversion feature would have been classified in equity under the guidance in Subtopic 815-40 and therefore qualify for the scope exception in ASU 2017-11. As permitted, the Company elected to adopt the accounting principles prescribed by ASU 2017-11 for the year ending December 31, 2017 and has recorded a cumulative-effect adjustment stemming from a change in accounting principle in its financial statements for the year ended December 31, 2017 measured retrospectively to the beginning of 2017. The cumulative effect adjustment appears at the beginning of 2017 in the Company’s Statement of Changes in Stockholders Deficit. The results of operations for the Company for year ended December 31, 2017 reflects application of the change in accounting principle from the beginning of 2017. The following table details the impact stemming from the cumulative effect of the change in accounting principle on the Company’s Balance Sheets as of the beginning of 2017. Balance Sheet Accounts Impacted by As Cumulative Reported after the Embedded derivative liability $ 228,718 $ (228,718 ) $ - Warrant liability 394,744 (394,744 ) - Additional paid in capital 40,469,272 11,924,665 52,393,937 Accumulated deficit (41,644,545 ) (11,301,203 ) (52,945,748 ) Because the Company has retroactively applied the change in accounting principle discussed above to the beginning of 2017, the Company is no longer reporting warrant derivative gains or losses for the warrants and embedded conversion feature beginning in 2017. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Fair Value of Financial Instruments The Company’s financial instruments consist of accounts receivable, accounts payable and accrued expenses, notes payable, embedded derivative liability and warrant liability. The carrying value of accounts receivable, accounts payable and accrued expenses approximate their fair value because of their short maturities. The Company believes the carrying amount of its notes payable approximate fair value based on rates and other terms currently available to the Company for similar debt instruments. The Company follows FASB ASC 820, “Fair Value Measurements and Disclosures,” and applies it to all assets and liabilities that are being measured and reported on a fair value basis. The statement requires that assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data Level 3: Unobservable inputs that are not corroborated by market data The level in the fair value within which a fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. Cash and Cash Equivalents For purposes of reporting cash flows, the Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and certificates of deposit and commercial paper with original maturities of 90 days or less to be cash or cash equivalents. Concentration of Credit Risk Involving Cash and Cash Equivalents The Company’s cash and cash equivalents are held at one financial institution. At times, the Company’s deposits may exceed Federal Deposit Insurance Corporation (FDIC) coverage limits. The Company has not experienced any losses from maintaining cash accounts in excess of federally insured limits. Allowance for Doubtful Accounts The Company considers allowances for doubtful accounts for estimated losses that may result from the inability of the Company’s customers to make required payments. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, such allowances may be required. Inventory Inventory principally consists of canisters and pigments and is stated at the lower of cost (determined by the first-in, first-out method) or market. Property and Equipment Property and equipment is stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, principally five to seven years. Maintenance and repairs of property are charged to operations, and major improvements are capitalized. Upon retirement, sale, or other disposition of property and equipment, the costs and accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in operations. Patents and Trademarks The current patent and trademark portfolios consist of 10 granted US patents and 1 granted European patent validated in 4 countries, 3 pending US and foreign patent applications, 1 registered US trademark, and 13 pending US and foreign trademark applications. Costs associated with the registration and legal defense of the patents have been capitalized and are amortized on a straight-line basis over the estimated lives of the patents which were determined to be 17 to 19 years. Long-Lived Assets The Company evaluates the recoverability of its long-lived assets in accordance with ASC 360 “Property, Plant, and Equipment.” The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets are measured by a comparison of the carrying amount of an asset to future cash flows expected to be generated by the asset, undiscounted and without interest or independent appraisals. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the assets. Related Parties Related parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operational decisions. Companies are also considered to be related if they are subject to common control or common significant influence. During the year ended December 31, 2018, the Company incurred $30,000 related to consulting services performed by a Director of the Board included in General and administrative on the Statement of Operations. Capitalized Software Costs incurred in connection with the development of software related to our proprietary digital products are accounted for in accordance with the Financial Accounting Standards Board Accounting Standards Codification ("ASC") 985 “Costs of Software to Be Sold, Leased or Marketed.” Costs incurred prior to the establishment of technological feasibility are charged to research and development expense. Software development costs are capitalized after a product is determined to be technologically feasible and is in the process of being developed for market. Amortization of capitalized software development costs begins once the product is available to the market. Capitalized software development costs are amortized over the estimated life of the related product, generally three years, using the straight-line method. The Company will evaluate its software assets for impairment whenever events or change in circumstances indicate that the carrying amount of such assets may not be recoverable. As of December 31, 2018, the Company capitalized $70,231. As of December 31, 2017, the Company had not capitalized any software development costs. The Company has not incurred a depreciation charge as the software was not available for use as of December 31, 2018. Notes Payable with detachable warrants In accordance with FASB ASC 470-20, “Debt with Conversion and Other Options,” the proceeds of notes payable with detachable stock purchase warrants have been allocated between the two based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance. The portion allocated to the warrants has been accounted for as a discount to the notes payable, and amortized over the term of the notes. Revenue Recognition The Company accounts for revenues according to ASC Topic 606, “ Revenue from Contracts with Customers” The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements: · identify the contract with a customer; · identify the performance obligations in the contract; · determine the transaction price; · allocate the transaction price to performance obligations in the contract; and · recognize revenue as the performance obligation is satisfied. During the year ended December 31, 2018, the Company’s revenues were primarily made up of revenue generated from printing labels with the Company’s technology. Income Taxes The Company follows FASB ASC 740, “Income Taxes,” when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. Tax years from 2014 through 2017 remain subject to examination by major tax jurisdictions. Stock-based Payments The Company accounts for stock-based compensation under the provisions of FASB ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. The Company accounts for stock-based compensation awards to non-employees in accordance with FASB ASC 505-50, “Equity-Based Payments to Non-Employees” (“FASB ASC 505-50”). Under FASB ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received, or the fair value of the equity instruments issued, whichever is more reliably measurable. All issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. Non-employee equity-based payments are recorded as an expense over the service period, as if the Company had paid cash for the services. At the end of each financial reporting period, prior to vesting or prior to the completion of the services, the fair value of the equity-based payments will be re-measured and the non-cash expense recognized during the period will be adjusted accordingly. Since the fair value of equity-based payments granted to non-employees is subject to change in the future, the amount of the future expense will include fair value re-measurements until the equity-based payments are fully vested or the service completed. Advertising Costs Advertising costs are expensed as incurred. Advertising costs were approximately $3,987 and $550 for the years ended December 31, 2018 and 2017 and are included in Sales and Marketing on the Statement of Operations. Research and Development Costs In accordance with FASB ASC 730, research and development costs are expensed when incurred. Research and development costs for the years ended December 31, 2018 and 2017 were $187,655 and $128,044. Basic and Diluted Net Income per Share of Common Stock The Company follows FASB ASC 260, “Earnings Per Share,” when reporting Earnings Per Share resulting in the presentation of basic and diluted earnings per share. Because the Company reported a net loss for each of the years presented, common stock equivalents, including preferred stock, stock options and warrants were anti-dilutive; therefore, the amounts reported for basic and diluted loss per share were the same. For the year ended December 31, 2018 and 2017, there were shares potentially issuable, that could dilute basic earnings per share in the future that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive to the Company’s losses during the years presented. For the year ended December 31, 2018 there were approximately 54,173,000 anti-dilutive shares consisting of 22,241,000 relating to warrants, 18,614,000 relating to options and 13,318,000 relating to preferred share agreements. For the year ended December 31, 2017 there were approximately 68,612,000 anti-dilutive shares consisting of 32,292,000 relating to warrants, 22,013,000 relating to options and 14,307,000 relating to preferred share agreements. Segment Information The Company is organized and operates as one operating segment wherein the Company’s patented technologies are utilized to address counterfeiting issues. In accordance with FASB ASC 280, “Segment Reporting” (“FASB ASC 280”), the chief operating decision-maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Since the Company operates in one segment and provides one group of similar products, all financial segment and product line information required by FASB ASC 280 can be found in the financial statements. Recently Adopted Accounting Pronouncements In July 2017, the Financial Accounting Standards Board (“FASB”) issued ASU 2017-11,“ Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part 1) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Non public Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception” (“ASU 2017-11”). Part I relates to the accounting or certain financial instruments with down round features in Subtopic 815-40, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. Down Round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced based on the pricing of future equity offerings. An entity still is required to determine whether instruments would be classified as equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017-11 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. Early adoption is permitted and may be applied on a retrospective basis, including in an interim period. The Company early adopted ASU 2017-11 during the interim period ended December 31, 2017 and retrospectively applied the adoption from January 1, 2017 (see Note 1, Change in Accounting Principle). Going Concern The Company has suffered recurring losses from operations and negative cash flows from operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. In order to continue as a going concern, develop a reliable source of revenues, and achieve a profitable level of operations the Company will need, among other things, additional capital resources. Management's plans to continue as a going concern include raising additional capital through increased sales of product and by sale of common shares. The Company’s business plans are dependent on the ability to raise capital through private placements of our common stock and/or preferred stock, through the possible exercise of outstanding options and warrants, through debt financing and/or through future public offering of our securities. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The Company’s existing cash resources are sufficient to sustain the Company’s operations during the next six months, however the Company may need to raise additional funds in the future in order to expand our business or if sales do not meet our internal budget.

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 2 – PROPERTY AND EQUIPMENT Equipment consists of the following: Year ended December 31, 2018 2017 Software, furniture and fixtures $ 200,000 $ 200,000 Equipment 3,223 3,223 Total 203,223 203,223 Less: accumulated depreciation (203,223 ) (203,223 ) Balance $ - $ - Depreciation of property and equipment was $0 and $0 for the years ended December 31, 2018 and 2017.

INTANGIBLE ASSETS

INTANGIBLE ASSETS	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	NOTE 2 – INTANGIBLE ASSETS Patents and Trademarks The current patent and trademark portfolios consist of 10 granted U.S. patents and 1 granted European patent validated in 4 countries, 4 pending U.S. and foreign patent applications, 4 registered U.S. trademarks, 1 registered EU foreign registration, and 8 pending U.S. and foreign trademark applications. Costs associated with the registration and legal defense of the patents have been capitalized and are amortized on a straight-line basis over the estimated lives of the patents which were determined to be 17 to 19 years. During the nine months ended September 30, 2019 and 2018, the Company capitalized $36,953 and $16,690, respectively, of patent and trademarks costs. Amortization expense for patents and trademarks was $5,662 and $5,034 for the three months ended September 30, 2019 and 2018, respectively, and $17,297 and $15,928 for the nine months ended September 30, 2019 and 2018, respectively. Capitalized Software Costs incurred in connection with the development of software related to our proprietary digital products are accounted for in accordance with the Financial Accounting Standards Board ASC 985 “Costs of Software to Be Sold, Leased or Marketed.” Costs incurred prior to the establishment of technological feasibility are charged to research and development expense. Software development costs are capitalized after a product is determined to be technologically feasible and is in the process of being developed for market. Amortization of capitalized software costs begins once the product is available to the market. Capitalized software costs are amortized over the estimated life of the related product, generally three years, using the straight-line method. The Company will evaluate its software assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. The Company had capitalized software costs of $141,656 and $70,231 as of September 30, 2019 and December 31, 2018, respectively. The Company has not incurred a depreciation charge because the software was not available for use as of September 30, 2019.	NOTE 3 – PATENTS AND TRADEMARKS During the years ended December 31, 2018 and 2017, the Company capitalized $38,505 and $2,650, respectively, for patent costs and trademarks. Amortization and impairment expense for patents and trademarks was $20,963 and $43,095 for the years ended December 31, 2018 and 2017.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 4 – INCOME TAXES The reconciliation of income tax expense computed at the U.S. federal statutory rate to the income tax provision for the years ended December 31, 2018 and 2017 is as follows (in thousands) Year Ended December 31 US 2018 2017 Income before income taxes $ (2,932 ) $ (3,385 ) Taxes under statutory US tax rates (616 ) (1,202 ) Increase (decrease) in taxes resulting from: Increase (decrease) in valuation allowance (92 ) 1,346 Non-deductible changes in derivative liability and share based transactions - 1 All other 857 - State taxes (149 ) (145 ) Income tax expense $ - $ - The increase in the Company's net increase in the valuation allowance was caused by continued net operating losses from ongoing operations. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Significant components of the Company's deferred tax assets and liabilities consist of the following: December 31, 2018 2017 US Net operating loss $ 8,316 $ 7,035 Share based compensation 447 1,800 Reserves and accruals (21 ) - Gross deferred tax assets 8,742 8,835 Less valuation allowance (8,742 ) (8,835 ) Total deferred tax assets - - Deferred tax liabilities: Total deferred tax liabilities - - Net deferred tax assets / (liabilities) $ - $ - As of December 31, 2018, the Company had federal and state net operating loss carry forwards of $36.9 million and $10.6 million, respectively that may be offset against future taxable income, subject to limitation under IRC Section 382, which begin to expire in 2019. No tax benefit has been reported in the December 31, 2018 or 2017 financial statements due to the uncertainty surrounding the realizability of the benefit, based on a more likely than not criteria and in consideration of available positive and negative evidence. Utilization of the net operating losses (NOL) carryforwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code (IRC) of 1986, as amended (the Code), as well as similar state provisions. These ownership changes may limit the amount of NOL carryforwards that can be utilized annually to offset future taxable income. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders. At the time of closing the books, the Company had not yet completed a study to determine the extent of the limitation. The Company applied the "more-likely-than-not" recognition threshold to all tax positions taken or expected to be taken in a tax return, which resulted in no unrecognized tax benefits as of December 31, 2018 and December 31, 2017, respectively. The Company’s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest and penalties on the balance sheets and has not recognized interest and/or penalties in the statements of operations and comprehensive loss for the years ended December 31, 2018 and 2017. The Company is subject to taxation in the United States and various state jurisdictions. The Company’s tax years from inception are subject to examination by the United States and state taxing authorities due to the carryforward of unutilized NOLs. On December 22, 2017, the United States enacted significant changes to the U.S. tax law following the passage and signing of H.R.1, “An Act to Provide for Reconciliation Pursuant to Titles II and V of the Concurrent Resolution on the Budget for Fiscal Year 2018” (the “Tax Act”) (previously known as “The Tax Cuts and Jobs Act”). The Tax Act significantly revised the U.S. corporate income tax regime by, among other things, lowering the corporate tax rate from 35% to 21%. The Tax Act reduced the U.S. corporate income tax rate reduction to 21% becomes effective January 1, 2018. The Company re-measured its deferred tax assets and liabilities as of December 31, 2017, applying the reduced corporate income tax rate and recorded a provisional decrease to the deferred tax assets and liabilities of $6.2 million, with a corresponding adjustment to the valuation allowance. There are no taxes payable as of December 31, 2018 or December 31, 2017.

NOTES PAYABLE

NOTES PAYABLE	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 5– NOTES PAYABLE Notes payable consists of the following as of December 31: Year ended December 31, 2018 2017 Series A notes payable; interest at 8% per annum; principal and $ - $ 50,000 Less: current portion - (50,000 ) Balance $ - $ - At December 31, 2018 and 2017 accrued interest on notes payable was $0 and $33,667. On October 28, 2009 the Company issued an unsecured note payable for $50,000. The note and accrued interest at 8% per annum were due in full in October 2011. The holder has never demanded payment. Since the note matured on September 30, 2011, the holder cannot commence an action to enforce payment of the note as the statute of limitations for the note expired on September 30, 2017. Applying guidance from ASC Topic 405-20, liabilities should be derecognized only when the obligor is legally released from the obligation, which occurred for the Company upon expiration of the statute of limitations. The carrying value of the note payable of $50,000 and accrued interest of $33,667 was derecognized in the year ended December 31, 2018 and recorded as Gain on derecognition of note payable and accrued interest included on the Statement of Operations. On January 24, 2017 and January 31, 2017, the Company issued notes payable to a director of the board in the amount of $20,000, in addition to warrants to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.40 per share and a term of five years. The notes bear interest at the rate of 10% per annum and are due on June 30, 2017. In accordance with FASB ASC 470-20, “Debt with Conversion and Other Options,” the proceeds of notes payable with detachable stock purchase warrants have been allocated between the two based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance. The warrants were valued at $15,896 fair value, using the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants. The warrant values were treated as a discount to the value of the note payable in accordance with FASB ASC 835-30-25, Recognition and were accreted over the term of the note payable for financial statement purposes. On February 13, 2017, the Company issued a note payable to a director of the board in the amount of $100,000 in addition to a warrant to purchase 5,000,000 shares of the Company’s common stock at an exercise price of $0.40 per share and a term of five years. The notes bear no interest and are due on June 30, 2017. In accordance with FASB ASC 470-20, “Debt with Conversion and Other Options,” the proceeds of notes payable with detachable stock purchase warrants have been allocated between the two based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance. The warrants were valued at $76,390 fair value, using the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants. The warrant values were treated as a discount to the value of the note payable in accordance with FASB ASC 835-30-25, Recognition and were accreted over the term of the note payable for financial statement purposes. On March 28, 2017, the Company issued a note payable to a director of the board in the amount of $25,000 in addition to a warrant to purchase 1,250,000 shares of the Company’s common stock at an exercise price of $0.40 per share and a term of five years. The notes bear no interest and are due on June 30, 2017. In accordance with FASB ASC 470-20, “Debt with Conversion and Other Options,” the proceeds of notes payable with detachable stock purchase warrants have been allocated between the two based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance. The warrants were valued at $21,300 fair value, using the Black-Scholes option pricing model to calculate the grant-date fair value of the warrants. The warrant values were treated as a discount to the value of the note payable in accordance with FASB ASC 835-30-25, Recognition and were accreted over the term of the note payable for financial statement purposes. On April 13, 2017, the Company issued notes payable to a director of the board in the principal amount of $10,000 in exchange for a loan bearing no interest maturing June 30, 2017. On April 26, 2017, the Company issued a secured promissory note (the “Note”) to a relative of director of the board in the principal amount of $30,000 in exchange for a loan bearing 10% interest maturing October 31, 2017. The Note is secured by a first lien on all assets of the Company in accordance with a security agreement entered into in connection with the Note. In the event the Company completes a financing of at least $750,000 prior to maturity of the Note, the principal of the Note will automatically convert into a number of shares of common stock of the Company equivalent to an investment of $60,000 under the terms of such financing. In the event of such a conversion or a voluntary prepayment by the Company, the Company will also pay six months of interest payments on the $60,000 principal of the Note. In May 2017, the Company issued notes payable to a director of the board in the principal amount of $60,000 in exchange for a loan bearing no interest maturing June 30, 2017. In June 2017, the Company issued notes payable to a director of the board in the principal amount of $36,000 in exchange for a loan bearing no annual interest maturing June 30, 2017. On June 30, 2017, all of these notes payable (including the Note) amounting to $360,000 and converting at $390,000 plus accrued interest of $6,101, except for the $50,000 note payable from 2009, were converted into 6,151,762 shares of the Company’s common stock and warrants to purchase 6,151,762 shares of the Company’s common stock at an exercise price of $0.15, with a term of five years. As of December 31, 2017, from the 6,151,762 shares of common stock and 6,151,762 warrants to purchase shares of the Company, 4,402,079 shares of common stock and 4,402,079 shares of warrants had been issued to convert $270,000 principal (including the Note) and $3,623 accrued interest. The fair value of the warrants issued in connection with the settlement of the notes payable were valued at $605,535 resulting in a Loss on settlement of related party notes payable of $331,912 included in the Statement of Operations. An increase of $30,000 in the Note principal upon conversion was included in Interest expenses in the Statement of Operations. As of December 31, 2017, 1,749,683 shares of common stock and 1,749,683 of warrants issuable upon conversion for $120,000 principal and $2,478 accrued interest had not yet been issued and as such the amount has been recorded as Common Stock payable included on the Balance Sheets. During the year ended December 31, 2018, those shares of common stock and warrants were issued and delivered. Pursuant to ASC 470-50- 40 Modifications and Extinguishments, the Company assessed the nature of the transaction and based on its assessment concluded it is a capital transaction in essence, and as such accounted for it through Additional Paid-In Capital with no gain or loss recognized in the Income Statement during the period.

CONVERTIBLE DEBT

CONVERTIBLE DEBT	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
CONVERTIBLE DEBT	NOTE 4 – CONVERTIBLE DEBT September 30, 2019 Convertible Debentures, due September 18, 2020: Principal value $ 600,000 Debt discount (371,522 ) Carrying value of convertible notes 228,478 Total short-term carrying value of Convertible Debentures $ 228,478 Embedded Derivative Liability: Fair value of derivative liability, December 31, 2018 $ - Fair value of derivative liability at issuance recorded as debt Discount 171,425 Change in fair value of derivative liability 36,109 Fair value of derivative liability, September 30, 2019 $ 207,534 On September 19, 2019, we completed the closing of $600,000 of secured Convertible Debentures (the “Debentures”) for gross proceeds of $540,000 after original issue discounts. As of September 18, 2019 (the “Effective Date”), we entered into two substantially identical securities purchase agreements (the “Securities Purchase Agreements”) with two purchasers (the “Purchasers”), which provided for the issuance of up to an aggregate of $1.2 million in principal amount of Debentures (the “Bridge Financing”) of which the first tranche of $600,000 has been issued. The Securities Purchase Agreements provided for the issuance of the Debentures due one year from the dates of issuance in two $600,000 tranches: the first tranche as described above, and the second tranche, at the discretion of the Purchasers and us, to occur any time after November 17, 2019. If, at any time after November 17, 2019, the Purchasers elect not to consummate the closing of the second tranche, then we may raise up to $600,000 from additional investors (including our affiliates) who will have a security interest on a pari passu In connection with the Bridge Financing, each of the Purchasers received commitment fees of $5,000 and 500,000 restricted shares (the “Commitment Shares”) of our common stock. The placement agent for the Debentures received a cash fee of 8% of the gross proceeds received at each closing and is entitled to receive warrants for 5% of the total number of securities received by the holders upon the conversion of the Debentures, or upon the conversion value of the Debentures if the Debentures are cash settled. These warrants will be exercisable at a price per share equal to 110% of the price of the securities paid by the Purchasers and will expire in five years. The first tranche of the Debentures will mature on September 18, 2020, and may be redeemed by us prior to the maturity date as described below. All unpaid principal due and payable on the maturity date will be paid in the form of common stock. Any principal or interest that is due under each of the Debentures, which is not paid by the respective maturity date, will bear interest at the rate of 18% per annum until it is satisfied in full. The Debentures are senior secured obligations secured pursuant to the terms of security agreements dated as of September 18, 2019 (the “Security Agreements”) by all of the Company’s assets. Each Purchaser is entitled, at any time, to convert all or any portion of the outstanding principal amount of its Debenture(s) plus any accrued interest into restricted shares of common stock. If we consummate a public offering within 180 calendar days of the Effective Date, then the conversion price will be the lesser of (a) $0.15 or (b) 70% multiplied of the price per share of the common stock we issue in the public offering (the “QPI Discounted Price”), subject to further adjustment as provided in the Debenture as well as subject in each case to equitable adjustments resulting from any stock splits, stock dividends, recapitalizations or similar events. Further, if we consummate a public offering of common stock which results in us receiving gross proceeds of at least $5 million within 180 calendar days of the Effective Date then we are obligated to repay the outstanding amounts owed under the Debentures, to the extent they are not converted and including the applicable redemption premium then in effect, within three days of consummation of such an offering. If any portion of the Debentures are outstanding on the 181st calendar day after the Effective Date, then the conversion price shall equal the lesser of (a) $0.15, (b) the QPI Discounted Price, or (c) 70% of the lowest volume-weighted average price (as reported by Bloomberg LP) of the common stock on any trading day during the 20 trading days immediately preceding the date of conversion of the Debenture (provided, further, that if either we are not DWAC operational at the time of conversion, the common stock is traded on the OTC Pink at the time of conversion, or the conversion price is less than $0.01 per share, then 70% will automatically adjust to 60%). The Debentures are subject to a “conversion blocker” such that the each of the Purchasers cannot convert the Debentures to the extent that the conversion would result in the Purchaser and its affiliates holding more than 4.99% of the outstanding common stock (which the Purchaser can increase to 9.99% upon at least 61 days prior written notice to us). So long as no event of default has occurred and is continuing under the Debentures, we may at our option call for redemption all or part of the Debentures prior to the maturity date, upon not more than two calendar days written notice, for an amount equal to: (i) if the redemption date is 90 calendar days or less from the date of issuance of the Debentures, 110% of the sum of the principal amount; (ii) if the redemption date is greater than or equal to 91 calendar days from the date of issuance of the Debentures and less than or equal to 150 calendar days from the date of issuance of the Debentures, 120% of the sum of the principal amount; (iii) if the redemption date is greater than or equal to 151 calendar days from the date of issuance of the Debentures and less than or equal to 180 calendar days from the date of issuance of the Debentures, 125% of the sum of the principal amount; and (iv) if either (1) the Debentures are in default but the holder consents to the redemption notwithstanding such default or (2) the redemption date is greater than or equal to 181 calendar days from the date of issuance of the Debentures, 130% of the sum of the principal amount. The Debentures include an adjustment provision that, subject to certain exceptions, reduces, at the Purchaser’s option, the conversion price if we issue common stock or common stock equivalents (including in variable rate transactions) at a price lower than the then-current conversion price of the Debentures. Any reverse stock split of our outstanding shares will also result in an adjustment of the conversion price of the Debentures. The Securities Purchase Agreements contain customary representations, warranties and covenants. In addition, pursuant to the Securities Purchase Agreements, the Purchasers were granted piggy-back registration rights such that, from September 18, 2019 until the earlier of March 18, 2021 or the date the Debentures have been converted and/or repaid in the entirety, if we contemplate making an offering of our common stock or securities convertible into our common stock registered for sale under the Securities Act of 1933, as amended, or propose to file a registration statement covering any of our securities (other than a registration statement filed by us within 45 days of the signing closing date with the placement agent in the Bridge Financing acting as the underwriter), then each of the Purchasers will have the right to include all or a pro rata share of its Commitment Shares, the common stock issuable upon conversion of the Debentures (the “Conversion Shares”), and, to the extent applicable, any other shares of capital stock or other securities of ours that are issued upon exchange of Conversion Shares and/or restricted stock held by the Purchaser (collectively, the “Purchaser’s Securities”). The conversion option, the QPI put and the put exercisable upon certain financing events are embedded derivatives that are collectively bifurcated at fair value, with subsequent changes in fair value recognized in the Statement of Operations. The fair value estimate is a Level 3 measurement as defined by ASC Topic 820, Fair Value Measurements and Disclosures, as it is based on significant inputs not observable in the market. The Company estimated the fair value of the monthly payment provision using a Monte Carlo Simulation, with 10,000 trials, with the following key inputs: September 30, 2019 Stock price $0.08-$0.10 Terms (years) 0.97-1.00 Volatility 153.9%-158.2% Risk-free rate 1.75%-1.87% Probability of QPI 50% The Company recorded a total of $380,218 debt discount upon the closing of Convertible Debt, including the $171,425 fair value of the embedded derivative liability, $70,100 fair value of the common stock issued, $78,693 of direct transaction costs incurred, and $60,000 original issue discount. The Debt discount is amortized to interest expense over the term of the loan. Amortization of the debt discount associated with the Debentures was $8,696 for the three-month and nine-month periods ended September 30, 2019 and was included in interest expense in the accompanying Statements of Operations.

CONVERTIBLE PREFERRED STOCK

CONVERTIBLE PREFERRED STOCK	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
CONVERTIBLE PREFERRED STOCK [Abstract]
CONVERTIBLE PREFERRED STOCK	NOTE 3 – CONVERTIBLE PREFERRED STOCK The Company is authorized to issue Series A Convertible Preferred Stock, par value of $0.001 per share (the “Series A”) and Series B Convertible Preferred Stock, par value of $0.001 per share (the “Series B”). As of September 30, 2019, there were no shares of Series A outstanding and 0.85 of a share of Series B outstanding. Each share of Series A and Series B has limited voting rights, is entitled to participate with the common stock on liquidation and holders of Series A and Series B are subject to beneficial ownership limitations. Series A Convertible Preferred Stock During the nine months ended September 30, 2019, 304,778 shares of Series A were converted into 6,095,569 shares of the Company’s common stock. Series B Convertible Preferred Stock During the nine months ended September 30, 2018, 0.07 of a share of Series B was converted into 599,362 shares of the Company’s common stock.	NOTE 6 – CONVERTIBLE PREFERRED STOCK The Company has outstanding Series A Preferred Stock (the “Series A”) and Series B Preferred Stock (the “Series B”). As of December 31, 2018, there were 37,564,767 authorized and 304,778 outstanding shares of Series A and 85 authorized and 0.85 outstanding shares of Series B. Each share of Series A and B has limited voting rights, is entitled to participate with the common stock on liquidation and holders of Series A and B have beneficial ownership limitations. Series A Convertible Preferred Stock During the year ended December 31, 2017, 73,000 shares of Series A Convertible Preferred Stock were converted into 1,460,000 shares of the Company’s Common Stock. During the year ended December 31, 2018, 20,000 shares of Series A Convertible Preferred Stock were converted into 400,000 shares of the Company’s Common Stock. Series B Convertible Preferred Stock During the year ended December 31, 2017, there were no conversions of Series B Convertible Preferred Stock into shares of the Company’s common stock. During the year ended December 31, 2018 0.07 shares of Series B Convertible Preferred Stock were converted into 599,362 shares of the Company’s Common Stock. Series C Convertible Preferred Stock The Series C Convertible Preferred Stock (the “Series C”) described below converted on June 30, 2017 and a Certificate of Withdrawal for the Series C Certificate of Designation was subsequently filed. On May 30, 2017, the Company entered into Securities Exchange Agreements (the “Agreements”) with the holders of approximately 87% of the outstanding shares of the Company’s 0% Series C and the holders of 100% of the outstanding shares of the Company’s 0% Series D Convertible Preferred Stock (the “Series D”) and certain warrants to purchase the Company’s common stock held by the Series C and Series D holders. The effectiveness of the Agreements was contingent upon the Company raising at least $500,000 in a debt or equity financing transaction which closed on June 30, 2017. Pursuant to the Agreements, the holders exchanged each share of Series C for 2.857 shares of common stock and each warrant for two shares of common stock. The Agreements also eliminate a covenant in the Securities Purchase Agreements with the Series C and Series D investors which adversely affects the Company’s ability to issue securities and incur debt. On July 19, 2017, the Company authorized the withdrawal of the Certificates of Designation for Series C and Series D and on July 13, 2017, the Company ratified the authorization to issue shares of common stock to the holders of Series C and Series D. On April 14, 2017, 375,000 shares of Series C were converted into 375,000 shares of the Company’s Common Stock. On June 30, 2017, pursuant to the Agreement, 1,537,500 shares of Series C were converted into 4,392,858 shares of the Company’s Common Stock; 3,087,500 shares of warrants were converted into 6,175,000 shares of the Company’s Common Stock, out of which 230,000 shares was issued to a director of the Board. $473,604 deemed dividend to Series C holders and $473,604 accretion of deemed distribution to Series C holders was recorded in conjunction with the transaction. Series D Convertible Preferred Stock The Series D described below converted on June 30, 2017 and a Certificate of Withdrawal Series D Certificate of Designation was subsequently filed. As noted, above, on May 30, 2017, the Company entered into Agreements with the holders of approximately 87% of the outstanding shares of the Company’s Series C and certain warrants to purchase the Company’s common stock held by the Series C holders. The Company had an oral agreement with the holder of the outstanding shares of the Company’s Series D to convert the Series D when the Series C converted. On July 13, 2017, the Company issued the Series D holder 2,482,145 shares of common stock upon conversion of the Series D and exchange of warrants issued with the Series D. On June 30, 2017, 166,750 shares of Series D were converted into 496,429 shares of the Company’s Common Stock; 667,000 shares of warrants were converted into 1,985,716 shares of the Company’s Common Stock. $123,274 deemed dividend to Series D holders and $123,274 accretion of deemed distribution to Series D holders was recorded in conjunction with the transaction.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 5 – STOCKHOLDERS’ EQUITY For each of the three and nine months ended September 30, 2019, the Company expensed $0 relative to restricted stock units. For the three and nine months ended September 30, 2018 the Company expensed $0 and $8,625, respectively, relative to restricted stock units. During the nine months ended September 30, 2019, the Company granted a total of 1,200,000 restricted stock awards to five directors of the Company for their services. The restricted stock awards vest in equal quarterly installments over a one-year period. On February 27, 2019, three directors resigned from the Company’s Board of Directors, effective March 1, 2019. This resulted in a cancellation of 320,000 shares related to the portion of the unvested restricted stock awards these directors had received. On September 18, 2019 a director resigned from the Company’s Board of Directors, effective immediately, resulting in a cancellation of 120,000 related to the portion of unvested restricted stock awards this director had received. On March 15, 2019, we engaged an advisor to provide consulting services under an Investor Relations and Advisory Agreement (the "Agreement"). Pursuant to the Agreement, we agreed to pay in advance of services a monthly fee of $5,000 in shares of restricted common stock to the consulting firm for consulting services. The number of shares to be issued will be calculated based on the closing price of our common shares on the 1st or preceding day of each month, if the 1st were to fall on a weekend or holiday. However, if the stock were to trade below $0.15, the calculation would be based on $0.15. The shares shall not have registration rights, and the shares may be sold subject to Rule 144. During the nine months ended September 30, 2019, the Company issued 171,324 shares of restricted common stock for a total expense of $26,167 related to these services. The Company expensed $84,434 and $168,654 in costs related to restricted stock awards for the three and nine months ended September 30, 2019, respectively. For the three and nine months ended September 30, 2018, the Company expensed $160,077 and $386,856, respectively, relative to restricted common stock. On May 29, 2019, a former director completed a cashless exercise of 200,000 warrants and was issued 71,774 shares of the Company’s common stock. See Note 6 – Stock Options, Restricted Stock and Warrants. During the nine months ended September 30, 2019, the Company issued 600,000 shares of restricted common stock for a total expense of $77,000 related to consulting services. During the nine months ended September 30, 2018, the Company issued 169,500 shares of restricted common stock for a total expense of $44,120 related to consulting services. On September 19, 2019, in connection with the Bridge Financing, the Company issued a total of 1,000,000 restricted shares of common stock with a fair value of $70,100. See Note 4 – Convertible Debt. During the nine months ended September 30, 2018, 37,500 restricted stock units vested in relation to a consulting services agreement and a total of $8,625 was expensed. During the nine months ended September 30, 2018, the Company granted a total of 600,000 shares of restricted common stock awards to two directors of the Company, each receiving 300,000 shares of restricted common stock upon joining the Board of Directors. On April 25, 2018, the Company approved the immediate vesting of all of the Company’s outstanding restricted common stock issued in 2017 and 2018 to non-employee directors of the Company. During the three months ended September 30, 2018, the Company granted a total of 1,425,000 shares of restricted common stock to the directors and the Chief Executive Officer of the Company for their services and 150,000 shares to one attorney, that vested quarterly over a one-year period. In 2017, the Company authorized a private placement with a maximum offering amount of $2,100,000 allowing investors to purchase units consisting of 715,000 shares of common stock and 715,000 five-year warrants exercisable at $0.15 per share. In January 2018 the Company’s Board of Directors increased the size of the private placement. During the nine months ended September 30, 2018, the Company raised gross proceeds of $1,154,211 for the purchase of 16,513,311 shares of common stock and 16,513,311 warrants. Of these amounts, gross proceeds of $530,777 for the purchase of 7,590,111 shares of common stock and 7,590,111 warrants related to purchases by directors and relatives of the directors of the Company. In January 2018, the Chairman of the Board of Directors, made a cashless exercise of 5,000,000 options related to services rendered in 2017, resulting in the issuance of 4,027,778 shares of common stock. See Note 6 – Stock Options, Restricted Stock and Warrants. On January 30, 2018, the Company authorized a 30-day offer, beginning on February 20, 2018, to the holders of the Company’s outstanding warrants exercisable at $0.15 to exercise their warrants at $0.10 per share. This authorization was extended until the latter of 30 days after the receipt of all Investment Letters, as defined below, in connection with the Settlement Shares, as defined below, or September 30, 2018. For the nine months ended September 30, 2018, 20,764,860 shares of warrants were exercised and a total of 20,764,860 shares of common stock were issued for gross proceeds of $2,076,486. Included in the above amounts are gross proceeds of $1,205,458 from directors which resulted in 12,054,576 warrants converted into the issuance of 12,054,576 common stock. The offer to exercise $0.15 warrants at $0.10 per share expired on September 30, 2018 and the Company did not extend the offer. In January 2018, a member of the Board exercised 104,876 warrants with an exercise price of $0.15 and a total of 104,876 shares of common stock were issued for gross proceeds of $15,731. On March 31, 2018, the Company entered into a Confidential Settlement Agreement (the “Settlement Agreement”) with Paul Klapper, a member of the Company’s Board at that time, and certain other parties named in the Settlement Agreement. Pursuant to the terms of the Settlement Agreement, the Company (i) paid a total of $500,000 (the “Settlement Amount”) to a fund controlled by Paul Klapper and an additional party, and (ii) issued a total of 1,000,000 shares of the Company’s common stock to the fund and the third party (the “Settlement Shares”). The shares were valued at $279,000 whereby $139,500 related to common stock issued to a related party and $139,500 related to common stock issued to a third party. The Settlement Agreement provides for cancellation as of March 31, 2018 of certain revenue sharing agreements between the Company and each of Mr. Klapper (or an affiliate) and the third party, and terminates the Company’s obligation to issue warrants to purchase 3.7 million shares of the Company’s common stock at an exercise price of $0.40 per share. Mr. Klapper joined the Board of Directors on July 14, 2017 and resigned as of March 31, 2018. In January 2018, the Company issued 1,749,683 shares of common stock and 1,749,683 warrants with an exercise price of $0.15 to Mr. Klapper relating to the Note payable conversion that took place in June 2017. On March 28, 2018, the Company accelerated the vesting of 150,000 shares of restricted common stock owned by Mr. Klapper. In April 2018, the former Chief Executive Officer of the Company exercised his warrants at an exercise price of $0.01 for gross proceeds of $1,000 resulting in an issuance of 100,000 shares. On July 31, 2018, a member of the Board exercised 1,439,524 warrants held by an entity under his control at an exercise price of $0.15 per share for a total price of $215,929. In August 2018, a warrant holder, made a cashless exercise of 366,047 warrants, whereby the warrant holder disposed of 190,386 shares to the Company as part of this exercise, amounting to an issuance of 175,661 shares. See Note 6 - Stock Options, Restricted Stock and Warrants.	NOTE 7 – STOCKHOLDERS’ EQUITY For the years ended December 31, 2018 and 2017, the Company expensed $8,625 and $6,750 relative to Restricted Stock Units. For the years ended December 31, 2018 and 2017, the Company expensed $446,265 and $60,075 relative to Restricted Stock awards. On September 8, 2017, the Company entered into a consulting agreement stipulating partial payment in restricted common stock. As of December 31, 2017, 120,000 shares have been issued. These shares were valued at the closing price of the Company’s common stock as they became due for a total of $12,000 for the year ended December 31, 2017. During the year ended December 31, 2018, the Company issued 49,500 shares and incurred $44,120 related to this agreement. During the year ended December 31, 2017, the Company also issued 1,605,175 shares of common stock and 1,605,175 shares of warrants to two directors of the Board for services already rendered under consulting agreements. The 1,605,175 shares of warrants have an exercise price of $0.15 per share and a term of five years. The common stock and warrants were valued and expensed for $285,807. On August 9, 2017, the Company granted 300,000 shares of restricted common stock to each of six non-employee directors and one attorney vesting quarterly over one year. The common stock was measured at fair value at the grant date and expensed based on the vesting schedule. Common stock related to the Company’s attorney were revalued as of the year end. During the year ended December 31, 2017, $60,075 compensation expense was recorded. During the year ended December 31, 2018, $111,105 compensation expense was recorded in relation to these awards. Of this amount $36,855 was related to the compensation of the six non-employee directors. As of December 31, 2018 and 2017, there is $0 and $84,105 unrecognized compensation cost related to these shares of restricted common stock. During 2017, 19,451,575 shares of common stock and 19,451,575 shares of warrants to purchase common stock were issued for gross proceeds of $1,360,250 from the sale of units with each unit consisting of 715,000 shares of common stock and 715,00 five-year warrants exercisable at $0.15 per share. Legal costs related to this offering amounted to $32,325 and were recorded in Additional Paid In Capital. Net proceeds related to the sale of common stock were $1,327,925 for the year ended December 31, 2017. In connection with the sale of common stock noted above, 8,712,275 shares were issued and 8,712,275 warrants to purchase common stock were issued for gross proceeds of $609,250 to directors of the Board and relatives of the directors of the Board. During 2017, 75,000 Restricted Stock Units were vested in relation to a consulting service agreement and a total of $6,750 was expensed. During 2017, 2,050,372 shares were issued as stock-based compensation with a total non-cash expense of $139,808. Of this amount 371,800 shares were issued to a director of the Board, for a total non-cash expense of $22,308. During 2017, 503,432 shares were issued for sale of common stock in prior years. Of this amount, 479,901 were related to two members of the Board. During the year ended December 31, 2018, 37,500 restricted stock units were vested in relation to a consulting service agreement and a total of $8,625 was expensed. During the year ended December 31, 2018, the Company granted a total of 600,000 restricted stock awards to two directors of the Company, each receiving 300,000 shares of restricted common stock, for joining the Board of Directors. On April 25, 2018 the Company approved the immediate vesting of all of the Company’s outstanding restricted common stock issued in 2017 and 2018 to non-employee directors of the Company. During the year ended December 31, 2018, $160,500 compensation expense was recorded in relation to this issuance. As of December 31, 2018, there is $0 unrecognized compensation cost related to these shares of restricted common stock. During the year ended December 31, 2018, the Company granted a total of 1,425,000 shares of restricted common stock to the directors and the Chief Executive Officer of the Company for their services and 150,000 shares to one attorney, vesting over a one-year period. During the year ended December 31, 2018, $174,660 compensation expense was recorded in relation to this issuance. As of December 31, 2018, there is $161,311 unrecognized compensation cost related to these shares of restricted common stock. In January 2018, the Chairman of the Board of Directors, made a cashless exercise of 5,000,000 options related to services in 2017, whereby the Chairman disposed of 972,222 shares to the Company as part of his exercise, amounting to an issuance of 4,027,778 shares, see Note 8. In relation to the 2017 private placement with a maximum offering amount of $2,100,000 allowing investors to purchase units consisting of 715,000 shares of common stock and 715,000 five-year warrants exercisable at $0.15 per share, the Company’s Board of Directors increased the size of the private placement by an additional amount beyond the $2,100,000 limit. During the year ended December 31, 2018 the Company raised gross proceeds of $1,153,645 for the purchase of 16,513,311 shares of common stock and 16,513,311 warrants. Of these amounts, gross proceeds of $530,777 for the purchase of 7,590,111 shares of common stock and 7,590,111 warrants related to current and then directors and relatives of the directors of the Company. On January 30, 2018, the Company authorized a 30-day offer, beginning on February 20, 2018, to the holders of the Company’s outstanding warrants exercisable at $0.15 to exercise their warrants at $0.10 per share. This authorization was extended until June 30, 2018. The Company authorized certain holders, who had sent in their exercise notices prior to June 30, 2018, to submit payment before July 27, 2018 and exercise their warrants at $0.10 per share. For the year ended December 31, 2018, 20,787,784 warrants were exercised and a total of 20,787,784 shares of common stock were issued for gross proceeds of $2,079,345. Included in the above amounts are gross proceeds of $1,205,458 from current and then directors in exchange for exercise of 12,054,576 warrants and issuance of 12,054,576 shares of common stock. In January 2018, a member of the Board exercised 104,876 warrants with an exercise price of $0.15 and a total of 104,876 shares of common stock were issued for gross proceeds of $15,731. On March 31, 2018, the Company entered into a Confidential Settlement Agreement (the “Settlement Agreement”) with Paul Klapper, a member of the Company’s Board, Stephen Silver, PFK Development Group, Ltd. (“PFKD”) and certain other parties named in the Settlement Agreement. Pursuant to the terms of the Settlement Agreement, the Company (i) paid a total of $500,000 (the “Settlement Amount”) to PFKD and Mr. Silver and (ii) issued them each 500,000 shares of the Company’s common stock (the “Settlement Shares”). The shares were valued at $279,000 whereby $139,500 related to common stock issued to a related party and $139,500 related to common stock issued to a third party. The Settlement Agreement provides for cancellation as of March 31, 2018 of certain revenue sharing agreements between the Company and each of Mr. Klapper, Mr. Silver and PFKD, and terminates the Company’s obligation to issue warrants to purchase 3.7 million shares of the Company’s common stock at an exercise price of $0.40 per share. Mr. Klapper joined the Board of Directors on July 14, 2017 and resigned as of March 31, 2018. In April 2018, the former Chief Executive Officer of the Company exercised his warrants at an exercise price of $0.01 for gross proceeds of $1,000 resulting in an issuance of 100,000 shares. On July 27, 2018 the Company cancelled 607,143 shares as a result of an over-issuance of shares to an investor in connection with the Company’s 2017 exchange. On July 31, 2018, a member of the Board exercised 1,439,524 warrants held by an entity under his control at an exercise price of $0.15 per share for a total price of $215,929.

STOCK OPTIONS, RESTRICTED STOCK

STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS	NOTE 6 – STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS During 2013, the Company adopted, and the shareholders approved, an incentive compensation plan (the “2013 Plan”) which served as the successor incentive compensation plan to a 2003 Stock Option Plan covering (i) 20,000,000 new shares of our common stock, plus (ii) the number of shares of our common stock subject to outstanding grants under the 2003 Plan as of the date of the 2013 Annual Meeting, plus (iii) the number of shares of our common stock remaining available for issuance under the 2003 Plan. Outstanding options for 7,990,000 shares of common stock have been issued under the 2013 Plan and the 2013 Plan will no longer be used for future grants. On November 14, 2017, the Company’s Board of Directors adopted and in 2018 our shareholders ratified the 2017 Equity Incentive Plan (the “2017 Plan”) which provides for the issuance of awards covering 13,000,000 shares of common stock under the 2017 Plan. The 2017 Plan provides that directors, officers, employees, and consultants of the Company will be eligible to receive equity incentives under the 2017 Plan at the discretion of the Board of Directors or the Compensation Committee of the Board of Directors (the “Compensation Committee”). The Compensation Committee may adopt rules and regulations to carry out the terms of the 2017 Plan. The Plan terminates on November 14, 2027 unless sooner terminated. The 2017 Plan is administered by the Compensation Committee which determines the persons to whom awards will be granted, the number of awards to be granted and the specific terms of each grant, including the vesting thereof, subject to the provisions of the 2017 Plan. In connection with incentive stock options issuable under the 2017 Plan, the exercise price of each option may not be less than 100% of the fair market value of the common stock on the date of the grant (or 110% of the fair market value in the case of a grantee holding more than 10% of the outstanding stock of the Company). Incentive stock options under all plans of the Company shall not exceed $1,000,000 per calendar year. If any employee shall have the right to first exercise any options in excess of $100,000 during any calendar year, the options in excess of $100,000 shall be deemed to be non-statutory stock options, including prices, duration, transferability and limitations on exercise. The Company issued non-statutory stock options pursuant to contractual agreements with non-employees. Options granted under the agreements are expensed when the related service or product is provided. Determining the appropriate fair value of stock-based awards requires the input of subjective assumptions. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value represent management’s best estimates and involve inherent uncertainties and judgments. During the nine months ended September 30, 2019 and 2018, the Company expensed $399,828 and $270,339, respectively, with respect to options. The following table presents the weighted-average assumptions used to estimate the fair value of the stock options granted during the nine months ended September 30, 2019: Risk Free Interest Rate 2.03 % Expected Volatility 433.91 % Expected Life (in years) 5.0 Dividend Yield 0 % Weighted average estimated fair value of options during the period $ 0.25 Options Outstanding Weighted - Average Aggregate Remaining Intrinsic Weighted- Contractual Value Number of Average Term (in 000’s) Shares Exercise Price (in years) (1) Balance as of December 31, 2018 18,613,529 $ 0.14 Granted 1,500,000 0.18 Balance September 30, 2019 20,113,529 $ 0.14 Exercisable at September 30, 2019 19,005,197 $ 0.14 3.2 $ 488 (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for options that were in-the-money at each respective period. The following table summarizes the activities for the Company’s unvested stock options for the nine months ended September 30, 2019: Unvested Options Weighted - Average Number of Unvested Grant Date Options Exercise Price Balance December 31, 2018 2,016,666 $ 0.18 Granted 1,500,000 0.18 Vested (2,408,334 ) 0.16 Balance September 30, 2019 1,108,332 $ 0.21 During the nine months ended September 30, 2019, the Company amended the Consulting Agreement it has with its Chief Operating Officer and granted him options to purchase 1,000,000 shares of common stock with an exercise price of $0.195 that vest annually in equal increments over a two-year period. Additionally, during the nine months ended September 30, 2019, the Company amended the Chief Operating Officer’s consulting agreement to provide, among other things, for a monthly consulting fee of $14,500 for services provided and to extend the term of the consulting agreement to March 1, 2021. In August 2019, the Company entered into an amendment (the “Amendment”) to the Employment Agreement, dated August 15, 2017, with Patrick White, the Chief Executive Officer of the Company (the “Employment Agreement”), which Employment Agreement automatically renewed on July 16, 2019, effective on August 15, 2019. Pursuant to the Amendment, the term was reduced to one year and Mr. White agreed to defer receipt of sums due him to improve the Company’s liquidity. Mr. White was due to receive $100,000 on August 15, 2019 representing deferred salary (the “Deferral Amount”) that he had previously agreed to defer over the two years of the initial term of his Employment Agreement. In the Amendment, Mr. White agreed to extend receipt of the Deferral Amount until August 15, 2020. In addition, he agreed to continue deferring 25% of his base salary over the one-year term until August 15, 2020. In connection with entering into the Amendment, the Company granted Mr. White 500,000 five-year fully vested incentive stock options under the Company’s 2017 Equity Incentive Plan exercisable at $0.14 per share. The following table summarizes the activities for the Company’s warrants for the nine months ended September 30, 2019: Warrants Outstanding Number of Weighted- Average Exercise Price Weighted - Average Remaining Contractual Term in years) Aggregate Intrinsic Value (in 000's) (1) Balance, December 31, 2018 22,240,833 $ 0.31 Exercised (200,000 ) 0.15 Expired (78,225 ) 0.26 Balance, September 30, 2019 21,962,608 $ 0.32 Exercisable at September 30, 2019 21,962,608 $ 0.32 3.0 $ -- (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying warrants and the closing stock price of $0.10 for our common stock on September 30, 2019. In May 2019, a former director made a cashless exercise of 200,000 warrants, whereby the warrant holder disposed of 128,226 shares of common stock to the Company as part of this exercise, amounting to an issuance of 71,774 shares of common stock.	NOTE 8 – STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS On December 17, 2003, the Company created the 2003 Stock Option Plan (the “2003 Plan”). Under the 2003 Plan, the Company is authorized to grant options to purchase up to 18,000,000 shares of common stock to the Company’s employees, officers, directors, consultants, and other agents and advisors. During 2013, the Company adopted a new incentive compensation plan (the “2013 Plan”). Under the 2013 Plan, the Company is authorized to grant awards of stock options, restricted stock, restricted stock units and other stock-based awards of up to an aggregate of 20,000,000 shares of common stock. The 2013 Plan is intended to permit stock options granted to employees under the 2013 Plan to qualify as Incentive Stock Options. All options granted under the 2013 Plan, which are not intended to qualify as Incentive Stock Options are deemed to be Non-Statutory Stock Options. On November 14, 2017, the Executive Committee of the Company’s Board of Directors adopted the 2017 Equity Incentive Plan (the “Plan”) which covers the potential issuance of 13 million shares of common stock. The Plan provides that directors, officers, employees, and consultants of the Company will be eligible to receive equity incentives under the Plan at the discretion of the Board or the Board’s Compensation Committee. The Board’s Compensation Committee may adopt rules and regulations to carry out the terms of the Plan. The Plan terminates on November 14, 2027 unless sooner terminated. The 2017 Plan is administered by a committee of the Board (“Compensation Committee”) which determines the persons to whom awards will be granted, the number of awards to be granted and the specific terms of each grant, including the vesting thereof, subject to the provisions of the plan. In connection with Incentive Stock Options, the exercise price of each option may not be less than 100% of the fair market value of the common stock on the date of the grant (or 110% of the fair market value in the case of a grantee holding more than 10% of the outstanding stock of the Company). The aggregate fair market value (determined at the time of the grant) of stock for which an employee may exercise Incentive Stock Options under all plans of the Company shall not exceed $1,000,000 per calendar year. If any employee shall have the right to exercise any options in excess of $100,000 during any calendar year, the options in excess of $100,000 shall be deemed to be Non-Statutory Stock Options, including prices, duration, transferability and limitations on exercise. The Company issued Non-Statutory Stock Options pursuant to contractual agreements with non-employees. Options granted under the agreements are expensed when the related service or product is provided. Determining the appropriate fair value of stock-based awards requires the input of subjective assumptions. The Company uses the Black-Scholes option pricing model to value its stock option awards. The assumptions used in calculating the fair value represent management’s best estimates and involve inherent uncertainties and judgments. The following table presents the weighted-average assumptions used to estimate the fair values of the stock options granted during the years ended December 31, 2018 and 2017: 2018 2017 Risk Free Interest Rate 2.30 % 1.90 % Expected Volatility 200.50 % 199.20 % Expected Life (in years) 5.0 5.0 Dividend Yield 0 % 0 % Weighted average estimated fair value of options during the period $ 0.17 $ 0.07 The following table summarizes the activities for the Company’s stock options for the year ended December 31, 2018 and 2017: Options Outstanding Weighted - Average Remaining Aggregate Weighted- Contractual Intrinsic Number of Average Term Value (in 000’) Shares Exercise Price (in years) (1) Balance as of December 31, 2016 3,282,647 $ 0.52 Granted 19,950,000 0.07 Forfeited/cancelled (1,219,117 ) 0.48 Balance December 31, 2017 22,013,529 $ 0.11 Granted 1,600,000 $ 0.27 Exercised (5,000,000 ) $ 0.07 Balance December 31, 2018 18,613,529 $ 0.14 3.9 Exercisable at December 31, 2018 16,596,863 $ 0.13 3.9 $2,113 (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for options that were in-the-money at each respective period. During the years ended December 31, 2018 and 2017, the aggregate intrinsic value of options exercised under the Company’s stock option plans was $2,113,368 and $3,480,567, respectively. The following table summarizes the activities for the Company’s unvested stock options for the year ended December 31, 2018 and 2017: Unvested Options Weighted - Average Grant Number of Unvested Date Exercise Price Options Balance December 31, 2016 - $ - Granted 19,950,000 0.07 Vested (16,833,333 ) 0.07 Cancelled/forfeited/expired (450,000 ) 0.08 Balance December 31, 2017 2,666,667 $ 0.06 Granted 1,600,000 0.27 Vested (2,250,001 ) 0.10 Balance December 31, 2018 2,016,666 $ 0.18 During the year ended December 31, 2017, 19,950,000 options were granted a weighted average exercise price of $0.07 with a term of five years. Of the 19,950,000 options, 450,000 options were issued to a director with a three-month vesting period, 10,000,000 to the Chairman of the Board vesting immediately, 7,000,000 were issued to the Chief Executive Officer of which 5,000,000 vested immediately and 2,000,000 vest over a period of two years and 2,000,000 were issued to a director vesting over a six month period. In February 2017, the Company also issued 500,000 options to purchase common stock to a consultant which vested immediately. During the year ended December 31, 2018, the Company amended the consulting agreement held with its Chief Operating Officer and granted him 1,000,000 stock options with an exercise price of $0.2102 with 500,000 stock options vesting immediately and the remaining 500,000 stock options vesting on February 28, 2019 subject to continuing to provide consulting services. In January 2018, the Chairman of the Board made a cashless exercise of 5,000,000 options related to services in 2017, whereby the Chairman disposed of 972,222 shares to the Company as part of his exercise, amounting to an issuance of 4,027,778 shares, see Note 7. In November 2018, 600,000 options were granted a weighted average exercise price of $0.37 with a term of five years. Of the 600,000 options, 500,000 options were issued to an employee of the Company vesting monthly over a six-month period, 100,000 to the Chief Financial Officer vesting quarterly over a one-year period. For the years ended December 31, 2018 and 2017, the Company expensed $329,193 and $1,295,741 with respect to the options. As of December 31, 2018, there was $198,438 unrecognized compensation cost related to outstanding stock options expected to vest over the weighted average of 3.9 years. The following table summarizes the activities for the Company’s warrants for the year ended December 31, 2018 and 2017: Warrants Outstanding Number of Shares Weighted- Average Exercise Price Weighted - Average Remaining Contractual Term in years) Aggregate Intrinsic Value (in 000's) (1) Balance, December 31, 2016 9,216,451 $ 1.82 Issued 33,080,629 0.20 Cancelled/Forfeited (10,004,500 ) 0.40 Balance, December 31, 2017 32,292,580 $ 0.30 Issued 18,727,769 0.15 Exercised (22,809,908 ) 0.11 Expired (1,019,608 ) 0.07 Cancelled/Forfeited (4,950,000 ) 0.40 Balance, December 31, 2018 22,240,833 $ 0.31 3.70 Exercisable at December 31, 2018 22,240,833 $ 0.31 3.70 $ 1,858 (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying warrants and the closing stock price of $0.22 for our common stock on December 31, 2018. All warrants were vested on the date of grant. During the year ended December 31, 2017, holders of Series C Preferred Stock and 3,087,500 warrants exchanged these securities for 6,175,000 shares of common stock. See Note 7. During the year ended December 31, 2017, holders of Series D Preferred Stock and 667,000 warrants exchanged these securities for 1,985,716 shares of common stock. See Note 7. During the year ended December 31, 2017, the Company issued 19,451,575 warrants to purchase common stock with an exercise price of $0.15 in connection to the sale of units occurring during the year. See Note 7. During the year ended December 31, 2017, the Company issued 4,402,079 warrants to purchase common stock with an exercise price of $0.15 in connection with the settlement or related party note payables. The fair value of the warrants accounted for in Additional Paid in Capital, for the year ended December 31, 2017, was $113,586. See Note 7. During the year ended December 31, 2017, a director was issued and then cancelled 6,250,000 warrants to purchase common stock in connection with the settlement of the related party note payable. During the year ended December 31, 2017, a director was issued 1,000,000 warrants to purchase common stock at an exercise price of $0.40 in connection with the issuance of notes payable. During the year ended December 31, 2017, the Company issued 1,976,975 warrants to directors of the Board to purchase common stock at an exercise price of $0.15 in connection with services provided. See Note 7. For the year ended December 31, 2018, the Company has received gross proceeds of $1,153,645 for the purchase of 16,513,311 shares of common stock and 16,513,311 warrants in relation to the private placement. See Note 7. In January 2018, the Company issued 1,749,683 shares of common stock and 1,749,683 warrants with an exercise price of $0.15 to Mr. Klapper relating to the Note payable conversion that took place in June 2017. Additionally, 3,700,000 warrants were forfeited. See Note 5. During the year ended December 31, 2018, in relation to the Settlement Agreement, the Company issued 464,775 warrants at an exercise price of $0.15 which were paid for in 2014 but had not been previously issued. See Note 7. For the year ended December 31, 2018, 20,787,784 shares of warrants were exercised and a total of 20,787,784 shares of common stock were issued for gross proceeds of $2,079,345. See Note 7. In January 2018, a member of the Board exercised 104,876 warrants with an exercise price of $0.15 and a total of 104,876 shares of common stock were issued for gross proceeds of $15,731, see Note 7. In April 2018, the former Chief Executive Officer of the Company exercised 100,000 warrants at an exercise price of $0.01 for gross proceeds of $1,000 resulting in an issuance of 100,000 shares, see Note 7. On July 31, 2018, a member of the Board exercised 1,439,524 warrants held by an entity under his control at an exercise price of $0.15 per share for a total price of $215,929. See note 7. In August 2018, a warrant holder, made a cashless exercise of 366,047 warrants, whereby the warrant holder disposed of 190,386 shares to the Company as part of this exercise, amounting to an issuance of 175,661 shares. In October 2018, a warrant holder, made a cashless exercise of 11,678 warrants, whereby the warrant holder disposed of 4,680 shares to the Company as part of this exercise, amounting to an issuance of 6,998 shares. During the year ended December 31, 2018 an additional 1,250,000 warrants were forfeited in relation to a note payable conversion occurring in the prior year.

DEBT FORGIVENESS

DEBT FORGIVENESS	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
DEBT FORGIVENESS	NOTE 9 – DEBT FORGIVENESS During the year ended December 31, 2018 the Company negotiated with certain vendors regarding balances outstanding for prior year services resulting in a Gain on accounts payable forgiveness included in the Statement of Operations for $352,008.

OPERATING LEASES

OPERATING LEASES	12 Months Ended
	Dec. 31, 2018
Leases [Abstract]
OPERATING LEASES	NOTE 10 – OPERATING LEASES For the year ended December 31, 2018 and 2017, total rent expense under leases amounted to $12,395 and $12,674. At December 31, 2018, the Company was not obligated under any non-cancelable operating leases.

MAJOR CUSTOMERS_VENDORS

MAJOR CUSTOMERS/VENDORS	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Risks and Uncertainties [Abstract]
MAJOR CUSTOMERS/VENDORS	NOTE 7 – CONCENTRATIONS Revenue For the three and nine months ended September 30, 2019, one customer represented 90% and 93% of revenues, respectively. Accounts Receivable As of September 30, 2019, one customer represented 20% of accounts receivable and one customer represented 76% of accounts receivable.	NOTE 11 – MAJOR CUSTOMERS/VENDORS During the year ended December 31, 2018, four customers accounted for 100.0% of total sales. During the year ended December 31, 2017 there were no sales. Generally, a substantial percentage of the Company's sales has been made to a small number of customers and is typically on an open account basis. During the years ended December 31, 2018 and 2017, the Company purchased 100.0% of pigment from one vendor. Additionally, during the years ended December 31, 2018 and 2017, the Company purchased 100.0% of canisters from one vendor. As of December 31, 2018, two customers accounted for 100% of total accounts receivable.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8 – SUBSEQUENT EVENTS In October 2019, the Company issued 33,333 shares of restricted common stock in relation to investor relation services. In November 2019, the Company issued 280,000 shares of restricted common stock in relation to consulting services. In November 2019, the Company issued 33,333 shares of restricted common stock in relation to investor relation services. In December 2019, the Company issued 240,000 shares of restricted common stock to a director.	NOTE 12 – SUBSEQUENT EVENTS In January 2019, 20,000 shares of Series A Convertible Preferred Stock were converted into 400,000 shares of the Company’s Common Stock. On February 27, 2019 three Board Members provided their resignations as members of the Company’s Board of Directors, effective March 1, 2019. On March 5, 2019 the Company appointed Mr. Eugene Robin to the Company’s Board of Directors. On March 20, 2019 the Company granted three directors the option of each receiving 240,000 shares of restricted stock or 240,000 restricted units, either of which shall vest over a one-year period in equal increments from March 15, 2019. Each of the directors elected to receive restricted stock awards. In March 2019, the Company appointed Dr. Arthur Laffer to its Board of Directors and granted 240,000 shares of restricted which shall vest over a one-year period in equal quarterly increments from March 15, 2019. In March 2019, 20,000 shares of Series A Convertible Preferred Stock were converted into 400,000 shares of the Company’s Common Stock.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Nature of Business	Nature of the Business The Company was incorporated in the State of Nevada on November 10, 1999. The Company is based in Rochester, New York and its common stock, par value $0.001 per share, is traded on the over-the-counter market and quoted on the OTCQB. The Company is a developmental stage technology solutions provider specializing in brand protection functions such as counterfeit prevention, authentication, serialization, track and trace features for labels, packaging and products. Leveraging our covert luminescent pigment, RainbowSecure®, which we began commercializing in 2018, we also developed the patent pending VeriPAS™ software system in 2018, which covertly and overtly serializes products to track a product’s “life cycle” for brand owners. VeriPAS™ is capable of fluorescing, decoding, and verifying invisible RainbowSecure® codes in the field – designed to allow investigators to quickly and efficiently authenticate product throughout the distribution chain, including warehouses, ports of entry, retail locations, and product purchased over the internet for inspection and investigative actions. This technology is coupled with a secure cloud based track and trace software engine which allows brands and investigators to see where products originate and where they are deployed with geo location mapping and intelligent programable alerts. Brand owners access the VeriPAS™ software over the internet. Brand owners can then set rules of engagement, establish marketing programs for customer engagement and control, and monitor and protect their products “life cycle.” We have not yet derived any revenue from our VeriPAS™ software system and have derived minimal revenue from the sale of our RainbowSecure® technology. The accompanying unaudited interim financial statements (the “Interim Statements”) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by U. S. generally accepted accounting principles (“GAAP”) for complete financial statements are not included herein. The Interim Statements should be read in conjunction with the financial statements and notes thereto included in the Company’s latest Annual Report on Form 10-K for the year ended December 31, 2018 as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2019. The accompanying Interim Statements are unaudited; however, in the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. The interim results for the three and nine months ended September 30, 2019 are not necessarily indicative of the results to be expected for the year ending December 31, 2019 or for any future interim periods. The Company’s activities are subject to significant risks and uncertainties, including the need to secure additional funding for working capital and to further develop the Company’s intellectual property. .	Nature of Business The Company was incorporated in the State of Nevada on November 10, 1999. The Company is based in Rochester, New York and its common stock, par value $0.001 per share, is traded on the over-the-counter market and quoted on the OTCQB. The Company is a technology pioneer in the anti-counterfeiting industry. This broad market encompasses counterfeiting of physical and material goods and products, as well as counterfeiting of identity in digital transactions. The Company is able to deliver security solutions for identification and authentication of people, products and packaging in a variety of applications in the security field for physical transactions and owns digital patents which are in the same field. The products can be used to manage and issue secure credentials, including national IDs, passports, driver licenses and access control credentials, as well as comprehensive authentication security software to secure physical and logical access to facilities, computer networks, internet sites and mobile applications. The Company’s activities are subject to significant risks and uncertainties, including the need to secure additional funding to further develop the Company’s patents.
Basis of Presentation	Basis of Presentation The accompanying financial statements are presented in accordance with GAAP.	Basis of Presentation The accompanying financial statements are presented in accordance with accounting principles generally accepted in the United States of America.
Change in Accounting Principle		Change in Accounting Principle In July 2017, the FASB issued ASU 2017-11. Part I relates to the accounting for certain financial instruments with down round features in Subtopic 815-40, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. Down round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced based on the pricing of future equity offerings. An entity still is required to determine whether instruments would be classified in equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. In the case where the exception from derivative accounting does not apply, warrants must be accounted for as a liability and recorded at fair value at the date of grant and re-valued at the end of each reporting period. The Company’s warrants and embedded conversion feature on its preferred stock (see Notes 6 and 7) include anti-dilution provisions characterized as down round features and have previously been accounted for as liabilities, with the fair value of the liabilities remeasured at each reporting date and the change in liabilities recorded as other non-operating income or loss. The Company had recorded a “Warrant liability” and “Embedded derivative liability” of $623,462, in the aggregate, and gain on the change in fair value of warrants and embedded derivative liability of $11,301,203, in the aggregate, in its “Accumulated deficit” as reported in its Balance Sheets for the year ended December 31, 2016 relating to the warrant liability and embedded derivative liability. The following table details the approximate fair value measurements within the fair value hierarchy of the Company’s derivative liabilities using Level 3 inputs: Total Balance, January 1, 2016 $ 1,802,375 Series C embedded derivative fair value, February 2016 1,235,000 Effect of conversion of Series C Preferred Stock on embedded derivative liability (350,500 ) Series C warrant liability fair value, February 2016 1,767,576 Series D embedded derivative fair value, October 2016 42,521 Series D warrant liability fair value, October 2016 181,942 Change in fair value of derivative liabilities (4,055,452 ) Balance, December 31, 2016 623,462 Cumulative adjustments related to change in accounting principle, January 1, 2017 (623,462 ) Balance, December 31, 2017 $ — Except for the down round features in the warrants and embedded conversion feature, the warrants and embedded conversion feature would have been classified in equity under the guidance in Subtopic 815-40 and therefore qualify for the scope exception in ASU 2017-11. As permitted, the Company elected to adopt the accounting principles prescribed by ASU 2017-11 for the year ending December 31, 2017 and has recorded a cumulative-effect adjustment stemming from a change in accounting principle in its financial statements for the year ended December 31, 2017 measured retrospectively to the beginning of 2017. The cumulative effect adjustment appears at the beginning of 2017 in the Company’s Statement of Changes in Stockholders Deficit. The results of operations for the Company for year ended December 31, 2017 reflects application of the change in accounting principle from the beginning of 2017. The following table details the impact stemming from the cumulative effect of the change in accounting principle on the Company’s Balance Sheets as of the beginning of 2017. Balance Sheet Accounts Impacted by As Cumulative Reported after the Embedded derivative liability $ 228,718 $ (228,718 ) $ - Warrant liability 394,744 (394,744 ) - Additional paid in capital 40,469,272 11,924,665 52,393,937 Accumulated deficit (41,644,545 ) (11,301,203 ) (52,945,748 ) Because the Company has retroactively applied the change in accounting principle discussed above to the beginning of 2017, the Company is no longer reporting warrant derivative gains or losses for the warrants and embedded conversion feature beginning in 2017.
Use of Estimates		Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.
Fair Value of Financial Instruments	Equity-linked Financial Instruments Certain of the Company’s debt instruments include embedded derivatives that require bifurcation from the host contract under the provisions of ASC 815, Derivatives and Hedging. Under this guidance, the Company recognizes the embedded derivatives at fair value and records a gain or loss resulting from the change in fair values at the end of each reporting period. In connection with issuance of the Debentures, described in Note 4 – Convertible Debt, after March 17, 2020, the Company could become contingently obligated to issue shares potentially in excess of its authorized share limit. Consequently, the ability to settle these obligations with shares would be unavailable causing these and other share-settled obligations to potentially be settled in cash. The Company applies a sequencing policy regarding share settlement wherein equity-linked financial instruments with the earliest issuance date would be settled first. Thus, all equity-linked financial instruments, which are convertible or exercisable into common stock, issued concurrent or subsequent to the Debentures are classified as derivative liabilities, with the exception of instruments related to employee share-based compensation.	Fair Value of Financial Instruments The Company’s financial instruments consist of accounts receivable, accounts payable and accrued expenses, notes payable, embedded derivative liability and warrant liability. The carrying value of accounts receivable, accounts payable and accrued expenses approximate their fair value because of their short maturities. The Company believes the carrying amount of its notes payable approximate fair value based on rates and other terms currently available to the Company for similar debt instruments. The Company follows FASB ASC 820, “Fair Value Measurements and Disclosures,” and applies it to all assets and liabilities that are being measured and reported on a fair value basis. The statement requires that assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data Level 3: Unobservable inputs that are not corroborated by market data The level in the fair value within which a fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety.
Cash and Cash Equivalents		Cash and Cash Equivalents For purposes of reporting cash flows, the Company considers all cash accounts, which are not subject to withdrawal restrictions or penalties, and certificates of deposit and commercial paper with original maturities of 90 days or less to be cash or cash equivalents.
Concentration of Credit Risk Involving Cash and Cash Equivalents		Concentration of Credit Risk Involving Cash and Cash Equivalents The Company’s cash and cash equivalents are held at one financial institution. At times, the Company’s deposits may exceed Federal Deposit Insurance Corporation (FDIC) coverage limits. The Company has not experienced any losses from maintaining cash accounts in excess of federally insured limits.
Allowance for Doubtful Accounts		Allowance for Doubtful Accounts The Company considers allowances for doubtful accounts for estimated losses that may result from the inability of the Company’s customers to make required payments. If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, such allowances may be required.
Inventory		Inventory Inventory principally consists of canisters and pigments and is stated at the lower of cost (determined by the first-in, first-out method) or market.
Property and Equipment		Property and Equipment Property and equipment is stated at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, principally five to seven years. Maintenance and repairs of property are charged to operations, and major improvements are capitalized. Upon retirement, sale, or other disposition of property and equipment, the costs and accumulated depreciation are eliminated from the accounts, and any resulting gain or loss is included in operations.
Patents and Trademarks		Patents and Trademarks The current patent and trademark portfolios consist of 10 granted US patents and 1 granted European patent validated in 4 countries, 3 pending US and foreign patent applications, 1 registered US trademark, and 13 pending US and foreign trademark applications. Costs associated with the registration and legal defense of the patents have been capitalized and are amortized on a straight-line basis over the estimated lives of the patents which were determined to be 17 to 19 years.
Long-Lived Assets		Long-Lived Assets The Company evaluates the recoverability of its long-lived assets in accordance with ASC 360 “Property, Plant, and Equipment.” The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets are measured by a comparison of the carrying amount of an asset to future cash flows expected to be generated by the asset, undiscounted and without interest or independent appraisals. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the assets.
Related Parties		Related Parties Related parties, which can be a corporation or individual, are considered to be related if the Company has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operational decisions. Companies are also considered to be related if they are subject to common control or common significant influence. During the year ended December 31, 2018, the Company incurred $30,000 related to consulting services performed by a Director of the Board included in General and administrative on the Statement of Operations.
Capitalized Software		Capitalized Software Costs incurred in connection with the development of software related to our proprietary digital products are accounted for in accordance with the Financial Accounting Standards Board Accounting Standards Codification ("ASC") 985 “Costs of Software to Be Sold, Leased or Marketed.” Costs incurred prior to the establishment of technological feasibility are charged to research and development expense. Software development costs are capitalized after a product is determined to be technologically feasible and is in the process of being developed for market. Amortization of capitalized software development costs begins once the product is available to the market. Capitalized software development costs are amortized over the estimated life of the related product, generally three years, using the straight-line method. The Company will evaluate its software assets for impairment whenever events or change in circumstances indicate that the carrying amount of such assets may not be recoverable. As of December 31, 2018, the Company capitalized $70,231. As of December 31, 2017, the Company had not capitalized any software development costs. The Company has not incurred a depreciation charge as the software was not available for use as of December 31, 2018.
Notes Payable with detachable warrants		Notes Payable with detachable warrants In accordance with FASB ASC 470-20, “Debt with Conversion and Other Options,” the proceeds of notes payable with detachable stock purchase warrants have been allocated between the two based on the relative fair values of the debt instrument without the warrants and of the warrants themselves at the time of issuance. The portion allocated to the warrants has been accounted for as a discount to the notes payable, and amortized over the term of the notes.
Revenue Recognition	Revenue Recognition The Company accounts for revenues according to Accounting Standards Codification (“ASC”) Topic 606, “ Revenue from Contracts with Customers” The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements: · identify the contract with a customer; · identify the performance obligations in the contract; · determine the transaction price; · allocate the transaction price to performance obligations in the contract; and · recognize revenue as the performance obligations are satisfied. During the three and nine months ended September 30, 2019, the Company’s revenues consisted of revenue primarily generated from customer’s printing labels utilizing the Company’s technology.	Revenue Recognition The Company accounts for revenues according to ASC Topic 606, “ Revenue from Contracts with Customers” The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements: · identify the contract with a customer; · identify the performance obligations in the contract; · determine the transaction price; · allocate the transaction price to performance obligations in the contract; and · recognize revenue as the performance obligation is satisfied. During the year ended December 31, 2018, the Company’s revenues were primarily made up of revenue generated from printing labels with the Company’s technology.
Income Taxes		Income Taxes The Company follows FASB ASC 740, “Income Taxes,” when accounting for income taxes, which requires an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for temporary differences between the financial statements and tax bases of assets and liabilities that will result in taxable or deductible amounts in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period plus or minus the change during the period in deferred tax assets and liabilities. Tax years from 2014 through 2017 remain subject to examination by major tax jurisdictions.
Stock-based Payments		Stock-based Payments The Company accounts for stock-based compensation under the provisions of FASB ASC 718, “Compensation—Stock Compensation”, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. The Company accounts for stock-based compensation awards to non-employees in accordance with FASB ASC 505-50, “Equity-Based Payments to Non-Employees” (“FASB ASC 505-50”). Under FASB ASC 505-50, the Company determines the fair value of the warrants or stock-based compensation awards granted as either the fair value of the consideration received, or the fair value of the equity instruments issued, whichever is more reliably measurable. All issuances of stock options or other equity instruments to non-employees as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued. Non-employee equity-based payments are recorded as an expense over the service period, as if the Company had paid cash for the services. At the end of each financial reporting period, prior to vesting or prior to the completion of the services, the fair value of the equity-based payments will be re-measured and the non-cash expense recognized during the period will be adjusted accordingly. Since the fair value of equity-based payments granted to non-employees is subject to change in the future, the amount of the future expense will include fair value re-measurements until the equity-based payments are fully vested or the service completed.
Advertising Costs		Advertising Costs Advertising costs are expensed as incurred. Advertising costs were approximately $3,987 and $550 for the years ended December 31, 2018 and 2017 and are included in Sales and Marketing on the Statement of Operations.
Research and Development Costs		Research and Development Costs In accordance with FASB ASC 730, research and development costs are expensed when incurred. Research and development costs for the years ended December 31, 2018 and 2017 were $187,655 and $128,044.
Basic and Diluted Net Income per Share of Common Stock	Basic and Diluted Net Income per Share of Common Stock The Company follows FASB ASC 260, “Earnings Per Share,” when reporting earnings per share resulting in the presentation of basic and diluted earnings per share. Because the Company reported a net loss for each of the periods presented, common stock equivalents, including preferred stock, stock options and warrants were anti-dilutive; therefore, the amounts reported for basic and diluted loss per share were the same. For each of the three and nine months ended September 30, 2019 and 2018, there were shares potentially issuable, that could dilute basic earnings per share in the future that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive to the Company’s losses during the years presented. For each of the three and nine months ended September 30, 2019, there were approximately 56,699,000 anti-dilutive shares consisting of 20,114,000 shares issuable upon exercise of options, 21,963,000 shares issuable upon exercise of warrants, 7,222,000 shares issuable upon conversion of preferred stock and 4,000,000 shares issuable upon conversion of convertible debentures. For the three and nine months ended September 30, 2018, there were approximately 41,237,000 anti-dilutive shares consisting of 18,014,000 shares issuable upon exercise of options, 9,909,000 shares issuable upon exercise of warrants and 13,314,000 shares issuable upon conversion of preferred stock.	Basic and Diluted Net Income per Share of Common Stock The Company follows FASB ASC 260, “Earnings Per Share,” when reporting Earnings Per Share resulting in the presentation of basic and diluted earnings per share. Because the Company reported a net loss for each of the years presented, common stock equivalents, including preferred stock, stock options and warrants were anti-dilutive; therefore, the amounts reported for basic and diluted loss per share were the same. For the year ended December 31, 2018 and 2017, there were shares potentially issuable, that could dilute basic earnings per share in the future that were excluded from the calculation of diluted earnings per share because their inclusion would have been anti-dilutive to the Company’s losses during the years presented. For the year ended December 31, 2018 there were approximately 54,173,000 anti-dilutive shares consisting of 22,241,000 relating to warrants, 18,614,000 relating to options and 13,318,000 relating to preferred share agreements. For the year ended December 31, 2017 there were approximately 68,612,000 anti-dilutive shares consisting of 32,292,000 relating to warrants, 22,013,000 relating to options and 14,307,000 relating to preferred share agreements.
Segment Information		Segment Information The Company is organized and operates as one operating segment wherein the Company’s patented technologies are utilized to address counterfeiting issues. In accordance with FASB ASC 280, “Segment Reporting” (“FASB ASC 280”), the chief operating decision-maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Since the Company operates in one segment and provides one group of similar products, all financial segment and product line information required by FASB ASC 280 can be found in the financial statements.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements Effective January 1, 2019, the Company adopted ASU No. 2018-07, Compensation – Stock Based Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”), which aligns accounting for share-based payments issued to nonemployees to that of employees under the existing guidance of Topic 718, with certain exceptions. This update supersedes previous guidance for equity-based payments to nonemployees under Subtopic 505-50, Equity – Equity-Based Payments to Non-Employees. The adoption of ASU 2018-07 did not have a material impact on the Company’s financial statements. Effective January 1, 2019, the Company adopted ASU No. 2016-02 – “Lease (Topic 842)” and the series of related Accounting Standards Updates that followed (collectively referred to as “Topic 842”) using the modified retrospective approach. The adoption of Topic 842 did not have a material impact on the Company’s financial statements	Recently Adopted Accounting Pronouncements In July 2017, the Financial Accounting Standards Board (“FASB”) issued ASU 2017-11,“ Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part 1) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Non public Entities and Certain Mandatorily Redeemable Non-controlling Interests with a Scope Exception” (“ASU 2017-11”). Part I relates to the accounting or certain financial instruments with down round features in Subtopic 815-40, which is considered in determining whether an equity-linked financial instrument qualifies for a scope exception from derivative accounting. Down Round features are features of certain equity-linked instruments (or embedded features) that result in the strike price being reduced based on the pricing of future equity offerings. An entity still is required to determine whether instruments would be classified as equity under the guidance in Subtopic 815-40 in determining whether they qualify for that scope exception. If they do qualify, freestanding instruments with down round features are no longer classified as liabilities. ASU 2017-11 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period. Early adoption is permitted and may be applied on a retrospective basis, including in an interim period. The Company early adopted ASU 2017-11 during the interim period ended December 31, 2017 and retrospectively applied the adoption from January 1, 2017 (see Note 1, Change in Accounting Principle).
Sequencing	Sequencing As of September 19, 2019, the Company adopted a sequencing policy whereby all equity-linked instruments issued prior to the closing of the $600,000 secured Convertible Debentures on September 19, 2019 may be classified as equity and all future equity-linked instruments may be classified as a derivative liability with the exception of instruments related to share-based compensation issued to employees or directors.
Going Concern	Going Concern The Company has suffered recurring losses from operations and negative cash flows from operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. In order to continue as a going concern, develop a reliable source of revenues, and achieve a profitable level of operations the Company will need, among other things, additional capital resources. Management's plans to continue as a going concern include raising additional capital through increased sales of product and raising additional capital through incurrence of debt and the sale of our common stock and other equity securities. On September 19, 2019, the Company received net proceeds of $461,307 from the Bridge Financing, described below in Note 4 – Convertible Debt. The Company’s business plans are dependent on the ability to raise capital through private placements of our common stock and/or preferred stock, through the possible exercise of outstanding options and warrants, through debt financing and/or through the future public offerings of our securities. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. As a result of the Bridge Financing, the Company’s existing cash resources are sufficient to sustain our operations through December 2019. The Company needs to raise additional funds in the future in order to remain operational past that date.	Going Concern The Company has suffered recurring losses from operations and negative cash flows from operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. In order to continue as a going concern, develop a reliable source of revenues, and achieve a profitable level of operations the Company will need, among other things, additional capital resources. Management's plans to continue as a going concern include raising additional capital through increased sales of product and by sale of common shares. The Company’s business plans are dependent on the ability to raise capital through private placements of our common stock and/or preferred stock, through the possible exercise of outstanding options and warrants, through debt financing and/or through future public offering of our securities. However, management cannot provide any assurances that the Company will be successful in accomplishing any of its plans. The Company’s existing cash resources are sufficient to sustain the Company’s operations during the next six months, however the Company may need to raise additional funds in the future in order to expand our business or if sales do not meet our internal budget.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Schedule of derivative liabilities using Level 3 inputs	The following table details the approximate fair value measurements within the fair value hierarchy of the Company’s derivative liabilities using Level 3 inputs: Total Balance, January 1, 2016 $ 1,802,375 Series C embedded derivative fair value, February 2016 1,235,000 Effect of conversion of Series C Preferred Stock on embedded derivative liability (350,500 ) Series C warrant liability fair value, February 2016 1,767,576 Series D embedded derivative fair value, October 2016 42,521 Series D warrant liability fair value, October 2016 181,942 Change in fair value of derivative liabilities (4,055,452 ) Balance, December 31, 2016 623,462 Cumulative adjustments related to change in accounting principle, January 1, 2017 (623,462 ) Balance, December 31, 2017 $ —
Schedule of Cumulative effect of Change in Accounting Principle	The following table details the impact stemming from the cumulative effect of the change in accounting principle on the Company’s Consolidated Balance Sheets as of the beginning of 2017. Balance Sheet Accounts Impacted by As Cumulative Reported after the Embedded derivative liability $ 228,718 $ (228,718 ) $ - Warrant liability 394,744 (394,744 ) - Additional paid in capital 40,469,272 11,924,665 52,393,937 Accumulated deficit (41,644,545 ) (11,301,203 ) (52,945,748 )

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2018
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	Equipment consists of the following: Year ended December 31, 2018 2018 Software, furniture and fixtures $ 200,000 $ 200,000 Equipment 3,223 3,223 Total 203,223 203,223 Less: accumulated depreciation (203,223 ) (203,223 ) Balance $ - $ -

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of reconciliation of federal statutory tax rate	The reconciliation of income tax expense computed at the U.S. federal statutory rate to the income tax provision for the years ended December 31, 2018 and 2017 is as follows (in thousands) Year Ended December 31 US 2018 2017 Income before income taxes $ (2,932 ) $ (3,385 ) Taxes under statutory US tax rates (616 ) (1,202 ) Increase (decrease) in taxes resulting from: Increase (decrease) in valuation allowance (92 ) 1,346 Non-deductible changes in derivative liability and share based transactions - 1 All other 857 - State taxes (149 ) (145 ) Income tax expense $ - $ -
Schedule of deferred tax assets and liabilities	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and amounts used for income tax purposes. Significant components of the Company's deferred tax assets and liabilities consist of the following: December 31, 2018 2017 US Net operating loss $ 8,316 $ 7,035 Share based compensation 447 1,800 Reserves and accruals (21 ) - Gross deferred tax assets 8,742 8,835 Less valuation allowance (8,742 ) (8,835 ) Total deferred tax assets - - Deferred tax liabilities: Total deferred tax liabilities - - Net deferred tax assets / (liabilities) $ - $ -

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2018
Debt Disclosure [Abstract]
Schedule of notes Payable	Notes payable consists of the following as of December 31: Year ended December 31, 2018 2017 Series A notes payable; interest at 8% per annum; principal and $ - $ 50,000 Less: current portion - (50,000 ) Balance $ - $ -

CONVERTIBLE DEBT (Tables)

CONVERTIBLE DEBT (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Schedule of convertible debt.	September 30, 2019 Convertible Debentures, due September 18, 2020: Principal value $ 600,000 Debt discount (371,522 ) Carrying value of convertible notes 228,478 Total short-term carrying value of Convertible Debentures $ 228,478 Embedded Derivative Liability: Fair value of derivative liability, December 31, 2018 $ - Fair value of derivative liability at issuance recorded as debt Discount 171,425 Change in fair value of derivative liability 36,109 Fair value of derivative liability, September 30, 2019 $ 207,534
Schedule of estimated the fair value	The Company estimated the fair value of the monthly payment provision using a Monte Carlo Simulation, with 10,000 trials, with the following key inputs: September 30, 2019 Stock price $0.08-$0.10 Terms (years) 0.97-1.00 Volatility 153.9%-158.2% Risk-free rate 1.75%-1.87% Probability of QPI 50%

STOCK OPTIONS, RESTRICTED STO_2

STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Share-based Payment Arrangement [Abstract]
Schedule of weighted-average assumptions	The following table presents the weighted-average assumptions used to estimate the fair value of the stock options granted during the nine months ended September 30, 2019: Risk Free Interest Rate 2.03 % Expected Volatility 433.91 % Expected Life (in years) 5.0 Dividend Yield 0 % Weighted average estimated fair value of options during the period $ 0.25	The following table presents the weighted-average assumptions used to estimate the fair values of the stock options granted during the years ended December 31, 2018 and 2017: 2018 2017 Risk Free Interest Rate 2.30 % 1.90 % Expected Volatility 200.50 % 199.20 % Expected Life (in years) 5.0 5.0 Dividend Yield 0 % 0 % Weighted average estimated fair value of options during the period $ 0.17 $ 0.07
Schedule of stock option activity	Options Outstanding Weighted - Average Aggregate Remaining Intrinsic Weighted- Contractual Value Number of Average Term (in 000’s) Shares Exercise Price (in years) (1) Balance as of December 31, 2018 18,613,529 $ 0.14 Granted 1,500,000 0.18 Balance September 30, 2019 20,113,529 $ 0.14 Exercisable at September 30, 2019 19,005,197 $ 0.14 3.2 $ 488 (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for options that were in-the-money at each respective period.	The following table summarizes the activities for the Company’s stock options for the year ended December 31, 2018 and 2017: Options Outstanding Weighted - Average Remaining Aggregate Weighted- Contractual Intrinsic Number of Average Term Value (in 000’) Shares Exercise Price (in years) (1) Balance as of December 31, 2016 3,282,647 $ 0.52 Granted 19,950,000 0.07 Forfeited/cancelled (1,219,117 ) 0.48 Balance December 31, 2017 22,013,529 $ 0.11 Granted 1,600,000 $ 0.27 Exercised (5,000,000 ) $ 0.07 Balance December 31, 2018 18,613,529 $ 0.14 3.9 Exercisable at December 31, 2018 16,596,863 $ 0.13 3.9 $2,113 (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock for options that were in-the-money at each respective period. During the years ended December 31, 2018 and 2017, the aggregate intrinsic value of options exercised under the Company’s stock option plans was $2,113,368 and $3,480,567, respectively.
Schedule of summary for the activities of unvested stock options	The following table summarizes the activities for the Company’s unvested stock options for the nine months ended September 30, 2019: Unvested Options Weighted - Average Number of Unvested Grant Date Options Exercise Price Balance December 31, 2018 2,016,666 $ 0.18 Granted 1,500,000 0.18 Vested (2,408,334 ) 0.16 Balance September 30, 2019 1,108,332 $ 0.21	The following table summarizes the activities for the Company’s unvested stock options for the year ended December 31, 2018 and 2017: Unvested Options Weighted - Average Grant Number of Unvested Date Exercise Price Options Balance December 31, 2016 - $ - Granted 19,950,000 0.07 Vested (16,833,333 ) 0.07 Cancelled/forfeited/expired (450,000 ) 0.08 Balance December 31, 2017 2,666,667 $ 0.06 Granted 1,600,000 0.27 Vested (2,250,001 ) 0.10 Balance December 31, 2018 2,016,666 $ 0.18
Schedule of warrant activity	The following table summarizes the activities for the Company’s warrants for the nine months ended September 30, 2019: Warrants Outstanding Number of Weighted- Average Exercise Price Weighted - Average Remaining Contractual Term in years) Aggregate Intrinsic Value (in 000's) (1) Balance, December 31, 2018 22,240,833 $ 0.31 Exercised (200,000 ) 0.15 Expired (78,225 ) 0.26 Balance, September 30, 2019 21,962,608 $ 0.32 Exercisable at September 30, 2019 21,962,608 $ 0.32 3.0 $ - (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying warrants and the closing stock price of $0.10 for our common stock on September 30, 2019.	The following table summarizes the activities for the Company’s warrants for the year ended December 31, 2018 and 2017: Warrants Outstanding Number of Weighted- Average Exercise Price Weighted - Average Remaining Contractual Term in years) Aggregate Intrinsic Value (in 000's) Balance, December 31, 2016 9,216,451 $ 1.82 Issued 33,080,629 0.20 Cancelled/Forfeited (10,004,500 ) 0.40 Balance, December 31, 2017 32,292,580 $ 0.30 Issued 18,727,769 0.15 Exercised (22,809,908 ) 0.11 Expired (1,019,608 ) 0.07 Cancelled/Forfeited (4,950,000 ) 0.40 Balance, December 31, 2018 22,240,833 $ 0.31 3.70 Exercisable at December 31, 2018 22,240,833 $ 0.31 3.70 $ 1,858 (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying warrants and the closing stock price of $0.22 for our common stock on December 31, 2018.

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Embedded derivative liability		$ 623,462		$ 623,462	$ 1,802,375
Additional paid in capital	$ 61,578,151	60,844,796	56,198,126
Accumulated deficit	$ (61,149,060)	$ (59,263,550)	(56,331,088)
Reported After Effect Of Change In Accountingt [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Additional paid in capital			52,393,937
Accumulated deficit			(52,945,748)
Cumulative Effect Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Embedded derivative liability			(228,718)
Warrant liability			(394,744)
Additional paid in capital			11,924,665
Accumulated deficit			$ (11,301,203)
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Embedded derivative liability				228,718
Warrant liability				394,744
Additional paid in capital				40,469,272
Accumulated deficit				$ (41,644,545)

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Beginning balance	$ 623,462	$ 1,802,375
Series C embedded derivative fair value, February 2016		1,235,000
Effect of conversion of Series C Preferred Stock on embedded derivative liability		(350,500)
Series C warrant liability fair value, February 2016		1,767,576
Series D embedded derivative fair value, October 2016		42,521
Series D warrant liability fair value, October 2016		181,942
Change in fair value of derivative liabilities		(4,055,452)
Cumulative adjustments related to change in accounting principle, January 1, 2017	(623,462)
Ending balance		$ 623,462

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)	Sep. 19, 2019USD ($)	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2018USD ($)shares	Sep. 30, 2019USD ($)$ / sharesshares	Sep. 30, 2018USD ($)shares	Dec. 31, 2018USD ($)NumberPatentsSegments$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)
Restructuring Cost and Reserve [Line Items]
Common stock, par value | $ / shares		$ 0.001		$ 0.001		$ 0.001	$ 0.001
Warrant liability and embedded derivative liability						$ 623,462		$ 623,462	$ 1,802,375
Amortization method of patents						Straight-line method
Interest rolled into principal							(30,000)
Capitalized software development costs						70,231	0
Advertising costs						3,987	550
Research and development costs		$ 804	$ 73,843	$ 7,055	$ 102,272	$ 187,655	$ 128,044
Anti-dilutive common stock equivalents, excluded from the calculation of earnings per share | shares		56,699,000	41,237,000	56,699,000	41,237,000	54,173,000	68,612,000
Number of operating segment | Segments						1
Accumulated deficit		$ (61,149,060)		$ (61,149,060)		$ (59,263,550)	$ (56,331,088)
Receivable of net proceeds					$ 1,154,211	$ 1,153,645	$ 1,327,925
Secured Convertible Debentures	$ 600,000
Bridge Financing [Member]
Restructuring Cost and Reserve [Line Items]
Receivable of net proceeds	$ 461,307
Warrant [Member]
Restructuring Cost and Reserve [Line Items]
Anti-dilutive common stock equivalents, excluded from the calculation of earnings per share | shares		21,963,000	9,909,000	21,963,000	9,909,000	22,241,000	32,292,000
Stock Option [Member]
Restructuring Cost and Reserve [Line Items]
Anti-dilutive common stock equivalents, excluded from the calculation of earnings per share | shares		20,114,000	18,014,000	20,114,000	18,014,000	18,614,000	22,013,000
Preferred share agreements [Member]
Restructuring Cost and Reserve [Line Items]
Anti-dilutive common stock equivalents, excluded from the calculation of earnings per share | shares		7,222,000	13,314,000	7,222,000	13,314,000	13,318,000	14,307,000
Convertible Debentures [Member]
Restructuring Cost and Reserve [Line Items]
Anti-dilutive common stock equivalents, excluded from the calculation of earnings per share | shares		4,400,000		4,400,000
Director [Member]
Restructuring Cost and Reserve [Line Items]
Interest rolled into principal						$ 30,000
Patents [Member]
Restructuring Cost and Reserve [Line Items]
Number of patents granted | Patents						1
Number of provisional patent applications pending | Number						3
Amortization method of patents				Straight-line basis
Patents [Member] | US
Restructuring Cost and Reserve [Line Items]
Number of patents granted | Patents						10
Trademarks [Member]
Restructuring Cost and Reserve [Line Items]
Number of patents granted | Patents						1
Number of provisional patent applications pending | Number						13
Amortization method of patents				Straight-line basis
Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Estimated useful lives of property and equipment						5 years
Minimum [Member] | Patents [Member]
Restructuring Cost and Reserve [Line Items]
Estimated lives of patents				17 years		17 years
Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Estimated useful lives of property and equipment						7 years
Maximum [Member] | Patents [Member]
Restructuring Cost and Reserve [Line Items]
Estimated lives of patents				19 years		19 years

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment, Net [Abstract]
Software, furniture and fixtures	$ 200,000	$ 200,000
Equipment	3,223	3,223
Total	203,223	203,223
Less: Accumulated depreciation	(203,223)	(203,223)
Balance

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Property, Plant and Equipment, Net [Abstract]
Depreciation of property and equipment	$ 0	$ 0

INTANGIBLE ASSETS (Details Narr

INTANGIBLE ASSETS (Details Narrative)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019USD ($)Number	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)Number	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Finite-Lived Intangible Assets [Line Items]
Amortization method					Straight-line method
Capitalized software costs | $			$ 141,656		$ 70,231
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Number of patents granted	10		10
Number of pending patents	4		4
Number of trademarks	4		4
Number of pending trademarks	8		8
Amortization method			Straight-line basis
Patents [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated lives of intangible assets			17 years		17 years
Patents [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Estimated lives of intangible assets			19 years		19 years
Patents [Member] | Foreign [Member]
Finite-Lived Intangible Assets [Line Items]
Number of trademarks	1		1
Patents [Member] | Europe [Member]
Finite-Lived Intangible Assets [Line Items]
Number of patents granted	1		1
Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization method			Straight-line basis
Patents And Trademark [Member]
Finite-Lived Intangible Assets [Line Items]
Capitalized patent costs and trademarks | $			$ 36,953	$ 16,690	$ 38,505	$ 2,650
Amortization expense | $	$ 5,662	$ 5,034	$ 17,297	$ 15,928	$ 20,963	$ 43,095

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Income before income taxes	$ (2,932)	$ (3,385)
Taxes under statutory US tax rates	(616)	(1,202)
Increase (decrease) in taxes resulting from:
Increase (decrease) in valuation allowance	(92)	1,346
Foreign tax rate differential		1
Non-deductible changes in derivative liability and share based transactions	857
State taxes	(149)	(145)
Income tax expense

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Net operating loss	$ 8,316	$ 7,035
Share based compensation	447	1,800
Reserves and accruals	(21)
Gross deferred tax assets	8,742	8,835
Less valuation allowance	(8,742)	(8,835)
Total deferred tax assets
Deferred tax liabilities:
Total deferred tax liabilities
Net deferred tax assets / (liabilities)

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Operating Loss Carryforwards [Line Items]
Provisional decrease to deferred tax assets and liabilities		$ 6,200,000
Fedral [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss ("NOL")	$ 36,900,000
State [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss ("NOL")	$ 10,600,000
Maximum [Member]
Operating Loss Carryforwards [Line Items]
Federal Statutory Rate	35.00%
Minimum [Member]
Operating Loss Carryforwards [Line Items]
Federal Statutory Rate	21.00%

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2017
Debt Instrument [Line Items]
Notes payable
Less: current portion		$ (50,000)
Balance
Series A Notes Payable Due At Maturity In October 2011 (Past Due) [Member]
Debt Instrument [Line Items]
Notes payable		50,000
Notes Payable [Member]
Debt Instrument [Line Items]
Less: current portion		$ (50,000)	$ (50,000)

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative)	Mar. 31, 2018USD ($)shares	Apr. 13, 2017USD ($)	Jan. 31, 2018$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Jun. 30, 2017USD ($)$ / sharesshares	May 31, 2017USD ($)	Apr. 26, 2017USD ($)	Mar. 28, 2017USD ($)Number$ / sharesshares	Feb. 13, 2017USD ($)Number$ / sharesshares	Jan. 31, 2017USD ($)$ / sharesshares	Oct. 28, 2009USD ($)	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2017USD ($)$ / sharesshares	Jul. 31, 2018$ / shares	Jul. 27, 2018$ / shares	Jan. 30, 2018$ / shares
Debt Instrument [Line Items]
Proceeds from issuance of notes payable													$ 281,000
Debt conversion, converted amount													$ 120,000
Exercise price (in dollars per share) | $ / shares				$ 0.15									$ 0.15			$ 0.15
Note payable balance				$ 50,000									$ 50,000
Accrued interest				33,667								0	33,667
Warrant value												605,535
Loss on settlement of related party notes payable	$ 279,000												$ 331,912
Increase decrease in notes payable												$ 30,000
Common Stock [Member]
Debt Instrument [Line Items]
Shares issued on conversion of debt (in shares) | shares													1,749,683
Warrant [Member]
Debt Instrument [Line Items]
Shares issued on conversion of debt (in shares) | shares													1,749,683
Exercise price (in dollars per share) | $ / shares																$ 0.10
Common Stock payable [Member]
Debt Instrument [Line Items]
Accrued interest				$ 2,478									$ 2,478
Sale of units [Member]
Debt Instrument [Line Items]
Number of common stock called by warrants (in shares) | shares				19,451,575									19,451,575
Exercise price (in dollars per share) | $ / shares				$ 0.15									$ 0.15
Related party note payables [Member]
Debt Instrument [Line Items]
Number of common stock called by warrants (in shares) | shares				4,402,079								4,402,079	4,402,079
Exercise price (in dollars per share) | $ / shares				$ 0.15								$ 0.15	$ 0.15
Maximum [Member] | Warrant [Member]
Debt Instrument [Line Items]
Exercise price (in dollars per share) | $ / shares				0.15									0.15
Board of Director [Member]
Debt Instrument [Line Items]
Exercise price (in dollars per share) | $ / shares				0.15									0.15
Board of Director [Member] | Common Stock [Member]
Debt Instrument [Line Items]
Number of common stock called by warrants (in shares) | shares	3,700,000
Board of Director [Member] | Warrant [Member]
Debt Instrument [Line Items]
Shares issued on conversion of debt (in shares) | shares			1,749,683
Exercise price (in dollars per share) | $ / shares			$ 0.15											$ 0.15	$ 0.10
Two directors [Member] | Warrant [Member]
Debt Instrument [Line Items]
Exercise price (in dollars per share) | $ / shares				$ 0.15									$ 0.15
Director [Member] | Related party note payables [Member]
Debt Instrument [Line Items]
Number of common stock called by warrants (in shares) | shares				6,250,000									6,250,000
Director [Member] | Issaunce of notes payable [Member]
Debt Instrument [Line Items]
Number of common stock called by warrants (in shares) | shares				1,000,000									1,000,000
Exercise price (in dollars per share) | $ / shares				$ 0.40									$ 0.40
Notes Payable [Member]
Debt Instrument [Line Items]
Proceeds from issuance of notes payable					$ 360,000							$ 50,000
Debt conversion, converted amount				$ 270,000	$ 390,000
Number of common stock called by warrants (in shares) | shares				6,151,762	6,151,762								6,151,762
Exercise price (in dollars per share) | $ / shares					$ 0.15
Fair value of warrant liability					$ 0
Note payable balance				$ 50,000	50,000								$ 50,000
Accrued interest				$ 33,667	$ 6,101							$ 0	$ 33,667
Notes Payable [Member] | Expected Life [Member]
Debt Instrument [Line Items]
Expected warrant term					5 years
Notes Payable [Member] | Transaction One [Member]
Debt Instrument [Line Items]
Number of common stock called by warrants (in shares) | shares				4,402,079									4,402,079
Accrued interest				$ 3,623									$ 3,623
Notes Payable [Member] | Warrant [Member]
Debt Instrument [Line Items]
Expected warrant term								5 years	5 years	5 years
Proceeds from issuance of notes payable								$ 25,000	$ 100,000	$ 20,000	$ 50,000
Number of common stock called by warrants (in shares) | shares								1,250,000	5,000,000	1,000,000
Exercise price (in dollars per share) | $ / shares								$ 0.40	$ 0.40	$ 0.40
Fair value of warrant liability								$ 21,300	$ 76,390	$ 15,896
Interest rate, notes payable											10.00%
Notes Payable [Member] | Warrant [Member] | Dividend Yield [Member]
Debt Instrument [Line Items]
Fair value, measurement input | Number								0	0
Notes Payable [Member] | Loan [Member]
Debt Instrument [Line Items]
Proceeds from issuance of notes payable		$ 10,000
Notes Payable [Member] | Loan [Member] | Board of Director [Member]
Debt Instrument [Line Items]
Proceeds from issuance of notes payable					$ 36,000	$ 60,000
Financing [Member]
Debt Instrument [Line Items]
Proceeds from issuance of notes payable							$ 750,000
Investment in common stock							60,000
Face amount							60,000
Promissory Note [Member] | Loan [Member]
Debt Instrument [Line Items]
Proceeds from issuance of notes payable							$ 30,000
Interest rate, notes payable							10.00%

CONVERTIBLE DEBT (Details)

CONVERTIBLE DEBT (Details) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
Principal value	$ 600,000	$ 600,000
Debt discount	(371,522)	(371,522)
Carrying value of convertible notes	228,478	228,478
Total short-term carrying value of convertible notes	228,478	228,478
Embedded Derivative Liability:
Fair value of derivative liability
Fair value of derivative liability at issuance recorded as debt Discount		171,425
Change in fair value of derivative liability	(36,109)	(36,109)
Fair value of derivative liability	$ 207,534	$ 207,534

CONVERTIBLE DEBT (Details 1)

CONVERTIBLE DEBT (Details 1) - Fair Value, Inputs, Level 3 [Member]	9 Months Ended
	Sep. 30, 2019Number
Stock Price [Member] | Minimum [Member]
Embedded Derivative Liability, Measurement Input	0.08
Stock Price [Member] | Maximum [Member]
Embedded Derivative Liability, Measurement Input	0.10
Volatility [Member] | Minimum [Member]
Embedded Derivative Liability, Measurement Input	153.9
Volatility [Member] | Maximum [Member]
Embedded Derivative Liability, Measurement Input	158.2
Risk-Free Rate [Member] | Minimum [Member]
Embedded Derivative Liability, Measurement Input	1.75
Risk-Free Rate [Member] | Maximum [Member]
Embedded Derivative Liability, Measurement Input	1.87
Probability of QPI [Member]
Embedded Derivative Liability, Measurement Input	50
Terms [Member] | Minimum [Member]
Embedded Derivative, Term	11 months 19 days
Terms [Member] | Maximum [Member]
Embedded Derivative, Term	1 year

CONVERTIBLE DEBT (Details Narra

CONVERTIBLE DEBT (Details Narrative) - USD ($)	Sep. 19, 2019	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Convertible debt	$ 600,000	$ 380,218	$ 380,218
Debentures for gross proceeds	540,000
Issuance of the debt tranche		600,000	$ 600,000
Shares issued during period					16,513,311	120,000
Description of debt conversion			If any portion of the Debentures are outstanding on the 181st calendar day after the Effective Date, then the conversion price shall equal the lesser of (a) $0.15, (b) the QPI Discounted Price, or (c) 70% of the lowest volume-weighted average price (as reported by Bloomberg LP) of the common stock on any trading day during the 20 trading days immediately preceding the date of conversion of the Debenture (provided, further, that if either we are not DWAC operational at the time of conversion, the common stock is traded on the OTC Pink at the time of conversion, or the conversion price is less than $0.01 per share, then 70% will automatically adjust to 60%).
Description of debt redemption			So long as no event of default has occurred and is continuing under the Debentures, we may at our option call for redemption all or part of the Debentures prior to the maturity date, upon not more than two calendar days written notice, for an amount equal to: (i) if the redemption date is 90 calendar days or less from the date of issuance of the Debentures, 110% of the sum of the principal amount; (ii) if the redemption date is greater than or equal to 91 calendar days from the date of issuance of the Debentures and less than or equal to 150 calendar days from the date of issuance of the Debentures, 120% of the sum of the principal amount; (iii) if the redemption date is greater than or equal to 151 calendar days from the date of issuance of the Debentures and less than or equal to 180 calendar days from the date of issuance of the Debentures, 125% of the sum of the principal amount; and (iv) if either (1) the Debentures are in default but the holder consents to the redemption notwithstanding such default or (2) the redemption date is greater than or equal to 181 calendar days from the date of issuance of the Debentures, 130% of the sum of the principal amount.
Amortization of debt discount			$ 8,696			$ 174,517
Fair value of embedded derivative liability					$ 623,462		$ 623,462	$ 1,802,375
Common stock issued in relation to Bridge Financing		70,100	70,100
Transaction costs		78,693	78,693
Original issue discount			$ 60,000
Public Offering [Member]
Description of debt			Each Purchaser is entitled, at any time, to convert all or any portion of the outstanding principal amount of its Debenture(s) plus any accrued interest into restricted shares of common stock. If we consummate a public offering within 180 calendar days of the Effective Date, then the conversion price will be the lesser of (a) $0.15 or (b) 70% multiplied of the price per share of the common stock we issue in the public offering (the “QPI Discounted Price”), subject to further adjustment as provided in the Debenture as well as subject in each case to equitable adjustments resulting from any stock splits, stock dividends, recapitalizations or similar events. Further, if we consummate a public offering of common stock which results in us receiving gross proceeds of at least $5 million within 180 calendar days of the Effective Date then we are obligated to repay the outstanding amounts owed under the Debentures, to the extent they are not converted and including the applicable redemption premium then in effect, within three days of consummation of such an offering.
Securities Purchase Agreement [Member] | Two Purchasers [Member]
Principal amount	$ 1,200,000
Description of debt tranche issuer	The Purchasers elect not to consummate the closing of the second tranche, then we may raise up to $600,000 from additional investors (including our affiliates) who will have a security interest on a pari passu basis with the Purchasers in the first tranche, so long as such investors agree not to convert the securities received until the Purchasers in the first tranche have completely converted the Debentures or been fully repaid.
Securities Purchase Agreement [Member] | Two Purchasers [Member] | First Tranche [Member]
Issuance of the debt tranche	$ 600,000
Maturity date	Sep. 18, 2020
Interest rate	18.00%
Securities Purchase Agreement [Member] | Two Purchasers [Member] | Second Tranche [Member]
Issuance of the debt tranche	$ 600,000
Securities Purchase Agreement [Member] | Bridge Financing [Member]
Commitment fee		$ 5,000	$ 5,000
Description of fee			The placement agent for the Debentures received a cash fee of 8% of the gross proceeds received at each closing and is entitled to receive warrants for 5% of the total number of securities received by the holders upon the conversion of the Debentures, or upon the conversion value of the Debentures if the Debentures are cash settled. These warrants will be exercisable at a price per share equal to 110% of the price of the securities paid by the Purchasers and will expire in five years.
Securities Purchase Agreement [Member] | Bridge Financing [Member] | Restricted Stock [Member]
Shares issued during period			500,000

CONVERTIBLE PREFERRED STOCK (De

CONVERTIBLE PREFERRED STOCK (Details Narrative) - USD ($)	Apr. 14, 2017	Jun. 30, 2017	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	May 30, 2017
Preferred stock, voting rights			Each share of Series A and Series B has limited voting rights, is entitled to participate with the common stock on liquidation and holders of Series A and Series B are subject to beneficial ownership limitations.		Each share of Series A and B has limited voting rights, is entitled to participate with the common stock on liquidation and holders of Series A and B have beneficial ownership limitations.
Common Stock [Member]
Conversion of shares of preferred stock to common stock (in shares)				599,362	599,362
Conversion of stock, shares converted (in shares)			(6,095,569)	(400,000)	(400,000)	(1,460,000)
Series A Convertible Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)			$ 0.001		$ 0.001	$ 0.001
Convertible Preferred Stock, authorized (in shares)			37,564,767		37,564,767	37,564,767
Convertible Preferred Stock, outstanding (in shares)			0		304,778	324,778
Conversion of stock, shares converted (in shares)			6,095,569	400,000	20,000	73,000
Conversion of shares of preferred stock to common stock (in shares)					400,000	1,460,000
Conversion of stock, shares converted (in shares)			304,778	20,000	(20,000)	73,000
Series B Convertible Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)			$ 0.001		$ 0.001	$ 0.001
Convertible Preferred Stock, authorized (in shares)			85		85	85
Convertible Preferred Stock, outstanding (in shares)			0.85		0.85	0.92
Conversion of stock, shares converted (in shares)				599,362	0.07
Conversion of shares of preferred stock to common stock (in shares)				(0.07)	(0.07)
Conversion of stock, shares converted (in shares)
Series C Convertible Preferred Stock [Member]
Conversion of stock, shares converted (in shares)	375,000	1,537,500
Conversion of shares of preferred stock to common stock (in shares)		4,392,858
Dividends		$ 473,604
Accretion of deemed distribution		$ 473,604
Conversion of stock, shares converted (in shares)
Series C Convertible Preferred Stock [Member]
Conversion of preferred stock, shares							2.857
Percentage of outstanding shares							87.00%
Series C Convertible Preferred Stock [Member] | Board of Director [Member]
Number of shares issued		230,000
Series C Convertible Preferred Stock [Member] | Common Stock [Member]
Conversion of stock, shares converted (in shares)		6,175,000				6,175,000
Series C Convertible Preferred Stock [Member] | Warrant [Member]
Conversion of stock, shares converted (in shares)		3,087,500				3,087,500
Series D Convertible Preferred Stock [Member]
Conversion of stock, shares converted (in shares)		166,750
Conversion of shares of preferred stock to common stock (in shares)		496,429
Dividends		$ 123,274
Accretion of deemed distribution		$ 123,274
Conversion of stock, shares converted (in shares)
Series D Convertible Preferred Stock [Member] | Common Stock [Member]
Conversion of stock, shares converted (in shares)		1,985,716
Series D Convertible Preferred Stock [Member] | Warrant [Member]
Conversion of stock, shares converted (in shares)		496,429

STOCKHOLDERS' EQUITY (Details N

STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)	Oct. 31, 2018	Aug. 31, 2018	Jul. 31, 2018	Jul. 27, 2018	Mar. 31, 2018	Aug. 09, 2017	Apr. 30, 2018	Jan. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Mar. 28, 2018	Jan. 30, 2018
Common stock issued									111,252,373		111,252,373		102,553,706	53,873,872
Common stock sold, value
Proceeds from issuance of convertible stock												$ 2,311,438	$ 2,312,005
Exercise price (in dollars per share)														$ 0.15		$ 0.15
Share-based payment for settlement agreement with shareholders					$ 279,000									$ 331,912
Proceeds from sale of common stock												1,154,211	$ 1,153,645	1,327,925
Common stock closing price														$ 12,000
Shares issued during period (in shares)													16,513,311	120,000
Incurred amount												1,154,211	$ 1,153,645	$ 1,360,250
Exercised total share price											200,000		22,809,908
Compensation expense													$ 111,105	60,075
Stock based compensation											$ 103,167	44,120	44,120	$ 139,808
Stock Based Compensation, Shares														2,050,372
Legal cost									$ 41,977	$ 64,897	$ 172,676	$ 362,371	416,772	$ 246,520
Compensation expenses for non employee directors													$ 36,855
Private Placement [Member]
Number of share cancelled				607,143
Third Party [Member]
Share-based payment for settlement agreement with shareholders					279,000
Related Party [Member]
Share-based payment for settlement agreement with shareholders					$ 139,500
Common Stock [Member]
Common stock sold														503,432
Common stock sold, value														$ 503
Restricted stock awards granted												2,212,500		2,175,000
Shares issued during period (in shares)										(607,143)		15,906,168	15,906,168	19,451,575
Incurred amount										$ (607)		$ 15,906	$ 15,906	$ 19,452
Stock Based Compensation, Shares														2,050,372
Common Stock [Member] | Common stock and warrant [Member]
Common stock sold														715,000
Warrant term														5 years
Board of Director [Member]
Proceeds from issuance of convertible stock												$ 2,076,486
Exercise price (in dollars per share)														$ 0.15
Issuance of shares cashless exercise of options related to services								4,027,778
Board of Director [Member] | Common stock and warrant [Member]
Gross proceeds from isssurance of common stock													1,153,645
Board of Director [Member] | Private Placement [Member]
Proceeds From Issuance of Private Placement								$ 2,100,000					$ 530,777
Board of Director [Member] | Settlement Agreement [Member]
Number of common stock called by warrants (in shares)					3,700,000
Common stock issued					500,000
Exercise price (in dollars per share)					$ 0.40
Amount of Settlement paid					$ 500,000
Share-based payment for settlement agreement with shareholders					$ 139,500
Board of Director [Member] | Common Stock [Member]
Number of common stock called by warrants (in shares)					3,700,000
Shares issued to convert accounts payable								1,749,683
Common stock sold												20,764,860	20,791,023
Proceeds from issuance of convertible stock												$ 12,054,576	$ 12,054,576
Restricted stock awards granted						300,000						300,000	300,000
Compensation expense													$ 160,500
Board of Director [Member] | Common Stock [Member] | Common stock and warrant [Member]
Shares issued during period (in shares)													16,513,311
Two Members Of Board [Member]
Common stock sold														503,432
Common stock sold, value														$ 479,901
Director [Member]
Restricted stock of vested, shares														450,000
Stock based compensation														$ 22,308
Stock Based Compensation, Shares														371,800
Consulting service agreement [Member]
Shares issued during period (in shares)													49,500
Incurred amount													$ 44,120
Restricted Stock Units (RSUs) [Member]
Restricted stock units, Expense													8,625	$ 6,750
Restricted Stock Units (RSUs) [Member] | Consulting service agreement [Member]
Restricted stock units, Expense													$ 8,625	$ 6,750
Restricted stock of vested, shares													37,500	75,000
Restricted stock of vested, amount													8,625	6,750
Restricted Stock Awards [Member]
Restricted stock units, Expense													$ 446,265	$ 60,075
Warrant [Member]
Exercise price (in dollars per share)																$ 0.10
Shares issued during period (in shares)													16,513,311
Warrant [Member] | Common stock and warrant [Member]
Common stock sold														715,000
Warrant term														5 years
Warrant [Member] | Private Placement [Member]
Gross proceeds from isssurance of common stock													$ 1,154,211
Warrant [Member] | Two directors [Member]
Exercise price (in dollars per share)														$ 0.15
Warrant [Member] | Board of Director [Member]
Shares issued to convert accounts payable								1,749,683
Common stock sold												20,764,860	20,787,784
Proceeds from issuance of convertible stock												$ 1,205,458	$ 1,205,458
Exercise price (in dollars per share)			$ 0.15	$ 0.10				$ 0.15
Proceeds from sale of common stock													$ 2,079,345
Shares issued during period (in shares)													20,787,784
Exercised total share price			1,439,524
Exercised total price			$ 215,929
Number of cashless exercise of warrants	11,678	366,047
Number of disposed share	4,680	190,386
Number of issuance share	6,998	175,661
Warrant [Member] | Board of Director [Member] | Common stock and warrant [Member]
Common stock sold													7,590,111
Restricted stock awards granted												300,000
Shares issued during period (in shares)													16,513,311
Warrant [Member] | Officer [Member]
Proceeds from issuance of convertible stock								$ 15,731
Exercise price (in dollars per share)								$ 0.15
Stock issued								104,876
Warrant [Member] | Consulting service agreement [Member] | Two directors [Member]
Common stock issued														1,605,175
Exercise price (in dollars per share)														$ 0.15
Warrant term														5 years
Stock and warrants issued during period, value														$ 285,807
Restricted Stock [Member]
Option vesting															150,000
Unrecognized compensation cost													$ 0	$ 84,105
Restricted Stock [Member] | Two Director [Member]
Restricted stock awards granted												600,000	600,000
Unrecognized compensation cost													$ 0
Restricted Stock [Member] | Director and Chief Executive Officer [Member]
Restricted stock of vested, shares										150,000			150,000
Restricted stock awards granted										1,425,000			1,425,000
Restricted stock awards granted term										1 year			1 year
Unrecognized compensation cost													$ 161,311
Stock Option [Member] | Warrant [Member] | Chief Executive Officer (Patrick White) [Member]
Exercise price (in dollars per share)							$ 0.01
Proceeds from sale of common stock							$ 1,000
Shares issued during period (in shares)							100,000
Incurred amount							$ 1,000
Stock Option [Member] | Board of Director [Member]
Issuance of shares cashless exercise of options related to services								5,000,000
Number of disposed share								972,222
Sale of units [Member]
Number of common stock called by warrants (in shares)														19,451,575
Exercise price (in dollars per share)														$ 0.15
Warrant term														5 years
Gross proceeds from isssurance of common stock														$ 1,360,250
Proceeds from sale of common stock														$ 1,327,925
Shares issued during period (in shares)														715,000
Number of warrant issued														71,500
Legal cost														$ 32,325
Sale of units [Member] | Directors of Board and relatives of directors of Board [Member]
Gross proceeds from isssurance of common stock														$ 609,250
Shares issued during period (in shares)														8,712,275
Number of warrant issued														8,712,275

STOCKHOLDERS' EQUITY (Details_2

STOCKHOLDERS' EQUITY (Details Narrative 1) - USD ($)	Oct. 31, 2018	Aug. 31, 2018	Jul. 31, 2018	Jul. 27, 2018	Mar. 31, 2018	Aug. 09, 2017	Apr. 30, 2018	Jan. 31, 2018	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Mar. 28, 2018	Jan. 30, 2018
Warrant Exercise price (in dollars per share)													$ 0.15		$ 0.15
Shares issued during period value											$ 1,154,211	$ 1,153,645	$ 1,360,250
Shares issued during period												16,513,311	120,000
Proceeds from issuance of convertible stock											$ 2,311,438	$ 2,312,005
Common stock issued										111,252,373		102,553,706	53,873,872
Share-based payment for settlement agreement with shareholders					$ 279,000								$ 331,912
Exercised total share price										200,000		22,809,908
Private Placement [Member]
Number of share cancelled				607,143
Third Party [Member]
Share-based payment for settlement agreement with shareholders					279,000
Related Party [Member]
Share-based payment for settlement agreement with shareholders					$ 139,500
Common Stock [Member]
Restricted stock awards granted											2,212,500		2,175,000
Common stock sold													503,432
Shares issued during period value									$ (607)		$ 15,906	$ 15,906	$ 19,452
Shares issued during period									(607,143)		15,906,168	15,906,168	19,451,575
Common Stock [Member] | Common stock and warrant [Member]
Common stock sold													715,000
Warrant term													5 years
Board of Director [Member]
Warrant Exercise price (in dollars per share)													$ 0.15
Issuance of shares cashless exercise of options related to services								4,027,778
Proceeds from issuance of convertible stock											$ 2,076,486
Board of Director [Member] | Private Placement [Member]
Proceeds From Issuance of Private Placement								$ 2,100,000				$ 530,777
Board of Director [Member] | Settlement Agreement [Member]
Warrant Exercise price (in dollars per share)					$ 0.40
Common stock issued					500,000
Amount of Settlement paid					$ 500,000
Share-based payment for settlement agreement with shareholders					$ 139,500
Number of common stock called by warrants (in shares)					3,700,000
Board of Director [Member] | Common Stock [Member]
Restricted stock awards granted						300,000					300,000	300,000
Common stock sold											20,764,860	20,791,023
Proceeds from issuance of convertible stock											$ 12,054,576	$ 12,054,576
Number of common stock called by warrants (in shares)					3,700,000
Shares issued to convert accounts payable								1,749,683
Board of Director [Member] | Common Stock [Member] | Common stock and warrant [Member]
Shares issued during period												16,513,311
Restricted Stock Units (RSUs) [Member]
Restricted stock/Restricted stock units, Expense												$ 8,625	$ 6,750
Restricted Stock Units (RSUs) [Member] | Consulting Service Agreement [Member]
Restricted stock vested, shares											37,500
Restricted stock vested, amount											8,625
Restricted Stock [Member]
Option vesting														150,000
Restricted Stock [Member] | Two Director [Member]
Restricted stock awards granted											600,000	600,000
Restricted Stock [Member] | Director and Chief Executive Officer [Member]
Restricted stock vested, shares									150,000			150,000
Restricted stock awards granted									1,425,000			1,425,000
Restricted stock awards granted term									1 year			1 year
Warrant [Member]
Warrant Exercise price (in dollars per share)															$ 0.10
Shares issued during period												16,513,311
Warrant [Member] | Common stock and warrant [Member]
Common stock sold													715,000
Warrant term													5 years
Warrant [Member] | Board of Director [Member]
Common stock sold											20,764,860	20,787,784
Warrant Exercise price (in dollars per share)			$ 0.15	$ 0.10				$ 0.15
Shares issued during period												20,787,784
Proceeds from issuance of convertible stock											$ 1,205,458	$ 1,205,458
Shares issued to convert accounts payable								1,749,683
Exercised total share price			1,439,524
Exercised total price			$ 215,929
Number of cashless exercise of warrants	11,678	366,047
Number of disposed share	4,680	190,386
Number of issuance share	6,998	175,661
Warrant [Member] | Board of Director [Member] | Common stock and warrant [Member]
Restricted stock awards granted											300,000
Common stock sold												7,590,111
Shares issued during period												16,513,311
Warrant [Member] | Member of Board [Member]
Warrant Exercise price (in dollars per share)			$ 0.15					$ 0.15
Shares issued during period value			$ 215,929					$ 15,731
Shares issued during period			1,439,524					104,876
Stock Option [Member] | Warrant [Member] | Chief Executive Officer (Patrick White) [Member]
Warrant Exercise price (in dollars per share)							$ 0.01
Shares issued during period value							$ 1,000
Shares issued during period							100,000
Stock Option [Member] | Board of Director [Member]
Issuance of shares cashless exercise of options related to services								5,000,000
Number of disposed share								972,222

STOCK OPTIONS, RESTRICTED STO_3

STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Share-based Payment Arrangement [Abstract]
Risk Free Interest Rate	2.03%	2.30%	1.90%
Expected Volatility	433.91%	200.50%	199.20%
Expected Life (in years)	5 years	5 years	5 years
Dividend Yield	0.00%	0.00%	0.00%
Weighted average estimated fair value of options during the period	$ 0.25	$ 0.17	$ 0.07

STOCK OPTIONS, RESTRICTED STO_4

STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS (Details 1) - USD ($)	Nov. 30, 2018	Nov. 18, 2018	Sep. 30, 2019		Dec. 31, 2018		Dec. 31, 2017
Number of Shares:
Granted	600,000	600,000					19,950,000
Weighted Average Exercise Price:
Granted	$ 0.37
Aggregate Intrinsic Value:
Balance as of December 31, 2018					$ 0
Stock Option [Member]
Number of Shares:
Balance, beginning			18,613,529		22,013,529		3,282,647
Granted			1,500,000		1,600,000		19,950,000
Exercised					(5,000,000)
Forfeited/cancelled							(1,219,117)
Balance, ending			20,113,529		18,613,529		22,013,529
Excercisable			19,005,197		16,596,863
Weighted Average Exercise Price:
Balance, beginning			$ 0.14		$ 0.11		$ 0.52
Granted			0.18				0.07
Exercised					0.07
Forfeited/cancelled							0.48
Balance, ending			0.14		0.14		$ 0.11
Exercisable			$ 0.14		$ 0.13
Weighted Average Remaining Contractual Term:
Balance as of December 31, 2018					3 years 10 months 24 days
Exercisable as of December 31, 2018			3 years 2 months 12 days		3 years 10 months 24 days
Aggregate Intrinsic Value:
Exercisable as of December 31, 2018			$ 488	[1]	$ 2,113	[2]
[1]	The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company's common stock for options that were in-the-money at each respective period.
[2]	The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company's common stock for options that were in-the-money at each respective period.During the years ended December 31, 2018 and 2017, the aggregate intrinsic value of options exercised under the Company's stock option plans was $2,113,368 and $3,480,567, respectively.

STOCK OPTIONS, RESTRICTED STO_5

STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS (Details 2) - USD ($)		Nov. 30, 2018	Nov. 18, 2018	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Number of Shares
Granted		600,000	600,000			19,950,000
Nonvested Stock Options [Member]
Number of Shares
Balance, Beginning				2,016,666	2,666,667
Granted				1,500,000	1,600,000	19,950,000
Vested				(2,408,334)	(2,250,001)	(16,833,333)
Cancelled/forfeited/expired						(450,000)
Balance, Ending				1,108,332	2,016,666	2,666,667
Weighted-Average Grant Date Fair Value
Balance, Beginning				$ 0.18	$ 0.06
Granted				0.18	0.27	0.07
Vested				0.16	0.10	0.07
Cancelled/forfeited/expired						0.08
Balance, Ending				$ 0.21	$ 0.18	$ 0.06
Aggregate Intrinsic Value
Exercisable	[1]
[1]	The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying warrants and the closing stock price of $0.10 for our common stock on September 30, 2019.

STOCK OPTIONS, RESTRICTED STO_6

STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS (Details 3) - USD ($)		9 Months Ended	12 Months Ended
		Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Number of Shares:
Balance, beginning		22,240,833	32,292,580	9,216,451
Issued			18,727,769	33,080,629
Exercised		(200,000)	(22,809,908)
Expired			(1,019,608)
Cancelled/Forfeited			(4,950,000)	(10,004,500)
Balance, ending		21,962,608	22,240,833	32,292,580
Exercisable as of December 31, 2018			22,240,833
Weighted Average Exercise Price:
Balance, beginning		$ 0.31	$ 0.30	$ 1.82
Issued			0.15	0.20
Exercised		0.15	0.11
Expired			0.07
Forfeited/canceled			0.40	0.40
Outstanding, ending		$ 0.32	0.31	$ 0.30
Exercisable as of December 31, 2018			$ 0.31
Weighted- Average Remaining Contractual Term:
Balance as of December 31, 2018			3 years 8 months 12 days
Exercisable as of December 31, 2018		3 years	3 years 8 months 12 days
Aggregate Intrinsic Value:
Exercisable as of December 31, 2018	[1]		$ 1,858
Closing stock price			$ 0.22
[1]	The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying warrants and the closing stock price of $0.22 for our common stock on December 31, 2018.

STOCK OPTIONS, RESTRICTED STO_7

STOCK OPTIONS, RESTRICTED STOCK AND WARRANTS (Details Narrative) - USD ($)

Feb. 28, 2019

Nov. 30, 2018

Nov. 18, 2018

Oct. 31, 2018

Aug. 31, 2018

Jul. 31, 2018

Nov. 14, 2017

Feb. 28, 2017

May 31, 2019

Apr. 30, 2018

Jan. 31, 2018

Jun. 30, 2017

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Dec. 31, 2017

Jul. 27, 2018

Mar. 31, 2018

Jan. 30, 2018

Dec. 17, 2003

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Option, expense

$ 399,828

$ 270,339

$ 329,193

$ 1,295,741

Granted

600,000

600,000

19,950,000

Weighted average exercise price, granted

$ 0.37

Shares issued during period value

1,154,211

$ 1,153,645

$ 1,360,250

Shares issued during period (in shares)

16,513,311

120,000

Exercise price (in dollars per share)

$ 0.15

$ 0.15

Weighted average exercise price

$ 0.37

Weighted avarage contractual term

5 years

5 years

Weighted avarage grant contractual term

5 years

Stock options expected to vest, weighted average

3 years 10 months 24 days

Unrecognized compensation cost

$ 198,438

Aggregate intrinsic value of options exercised

$ 2,113,368

$ 3,480,567

Common stock issued

111,252,373

102,553,706

53,873,872

Aggregate intrensic value

$ 0

Warrants issued in conjunction with related party notes payable

$ 113,586

Proceeds from issuance of common stock

1,154,211

1,153,645

1,327,925

Common Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares issued during period value

$ (607)

$ 15,906

$ 15,906

$ 19,452

Shares issued during period (in shares)

(607,143)

15,906,168

15,906,168

19,451,575

Shares issued in conversion of debt

1,749,683

Number of warrants exercised

4,027,778

4,027,778

Cashless exercise of warrants (in shares)

71,774

182,659

Additional Paid-In Capital [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares issued during period value

$ 607

$ 1,138,305

$ 1,137,739

$ 1,340,798

Warrants issued in conjunction with related party notes payable

$ 113,586

Series C Convertible Preferred Stock [Member] | Common Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Preferred stock converted in to common stock

6,175,000

6,175,000

Series D Convertible Preferred Stock [Member] | Common Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Preferred stock converted in to common stock

1,985,716

Board of Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Issuance of shares cashless exercise of options related to services

4,027,778

Exercise price (in dollars per share)

$ 0.15

Board of Director [Member] | Common Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of common stock called by warrants (in shares)

3,700,000

Chairman of Board [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vested

10,000,000

Disposed shares related to services

972,222

Shares issued during period (in shares)

4,027,778

Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vested

450,000

Chief Executive Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vested

5,000,000

Shares issued during period (in shares)

7,000,000

Chief Executive Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vested

2,000,000

Weighted avarage contractual term

2 years

Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vested

2,000,000

Weighted avarage contractual term

6 months

Chief Operating Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Monthly fee

$ 14,500

Chief Operating Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Granted

1,000,000

Exercise price of unvested options (in dollars per share)

$ 0.195

Term of unvested options

2 years

Consultant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of options issued

500,000

Employee [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Forfeited warrants

769,117

Weighted avarage contractual term

6 months

Number of options issued

500,000

Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Forfeited warrants

450,000

Chief Executive Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Weighted avarage contractual term

1 year

Number of options issued

100,000

Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant issued

1,976,975

Mr. Klapper [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares issued in conversion of debt

1,749,683

Exercise price (in dollars per share)

$ 0.15

Former Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares issued during period (in shares)

71,774

Cashless exercise of warrants (in shares)

200,000

Former Director [Member] | Common Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Cashless exercise of warrants (in shares)

128,226

Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise price, description

In connection with incentive stock options issuable under the 2017 Plan, the exercise price of each option may not be less than 100% of the fair market value of the common stock on the date of the grant (or 110% of the fair market value in the case of a grantee holding more than 10% of the outstanding stock of the Company).

In connection with Incentive Stock Options, the exercise price of each option may not be less than 100% of the fair market value of the common stock on the date of the grant (or 110% of the fair market value in the case of a grantee holding more than 10% of the outstanding stock of the Company).

Granted

1,500,000

1,600,000

19,950,000

Weighted average exercise price, granted

$ 0.18

$ 0.07

Forfeited warrants

1,219,117

Number of warrants exercised

5,000,000

Term of unvested options

3 years 10 months 24 days

Stock Option [Member] | Board of Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Issuance of shares cashless exercise of options related to services

5,000,000

Number of disposed share

972,222

Stock Option [Member] | Chief Executive Officer [Member] | Warrant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares issued during period value

$ 1,000

Shares issued during period (in shares)

100,000

Exercise price (in dollars per share)

$ 0.01

Number of warrants exercised

100,000

Proceeds from issuance of common stock

$ 1,000

Stock Option [Member] | Consulting Agreement [Member] | Chief Operating Officer [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vested

500,000

Granted

1,000,000

Exercise price (in dollars per share)

$ 0.2102

Stock Option [Member] | Consulting Agreement [Member] | Chief Operating Officer [Member] | Subsequent Event [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Vested

500,000

Warrant [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares issued during period (in shares)

16,513,311

Shares issued in conversion of debt

1,749,683

Exercise price (in dollars per share)

$ 0.10

Number of warrants exercised

1,250,000

Warrant [Member] | Series C Convertible Preferred Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Preferred stock converted in to common stock

3,087,500

3,087,500

Warrant [Member] | Series D Convertible Preferred Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Preferred stock converted in to common stock

667,000

Warrant [Member] | Board of Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares issued during period (in shares)

20,787,784

Shares issued in conversion of debt

1,749,683

Exercise price (in dollars per share)

$ 0.15

$ 0.15

$ 0.10

Number of warrants exercised

20,787,784

Number of cashless exercise of warrants

11,678

366,047

Number of disposed share

4,680

190,386

Number of issuance share

6,998

175,661

Proceeds from issuance of common stock

$ 2,079,345

Warrant [Member] | Member of Board [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares issued during period value

$ 215,929

$ 15,731

Shares issued during period (in shares)

1,439,524

104,876

Exercise price (in dollars per share)

$ 0.15

$ 0.15

Number of warrants exercised

104,876

Warrant [Member] | Director [Member] | Notes Payable [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise price (in dollars per share)

$ 0.40

Preferred stock converted in to common stock

1,000,000

Warrant [Member] | Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise price (in dollars per share)

$ 0.15

Warrant [Member] | Mr. Klapper [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares issued in conversion of debt

1,749,683

Sale of units [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares issued during period (in shares)

715,000

Exercise price (in dollars per share)

$ 0.15

Number of common stock called by warrants (in shares)

19,451,575

Number of warrant issued

71,500

Proceeds from issuance of common stock

$ 1,327,925

Related party note payables [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Exercise price (in dollars per share)

$ 0.15

$ 0.15

Number of common stock called by warrants (in shares)

4,402,079

4,402,079

Related party note payables [Member] | Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of common stock called by warrants (in shares)

6,250,000

Stock Option 2003 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares authorized to be granted under plan

18,000,000

Stock Option 2003 Plan [Member] | Stock Options, Restricted Stock and Units, and Other Stock-based Awards [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of shares authorized to be granted under plan

20,000,000

Stock Option 2013 Plan [Member] | Stock Options, Restricted Stock and Units, and Other Stock-based Awards [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares issued during period (in shares)

7,990,000

Equity Incentive Plan 2017 [Member] | Board of Director [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Shares issued during period (in shares)

13,000,000

DEBT FORGIVENESS (Details Narra

DEBT FORGIVENESS (Details Narrative)	12 Months Ended
	Dec. 31, 2018USD ($)
Debt Disclosure [Abstract]
Gain on accounts payable forgiveness	$ 352,009

OPERATING LEASES (Details Narra

OPERATING LEASES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Leases [Abstract]
Total rent expense under leases	$ 12,395	$ 12,674

MAJOR CUSTOMERS_VENDORS (Detail

MAJOR CUSTOMERS/VENDORS (Details Narrative) - Number	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Dec. 31, 2018	Dec. 31, 2017
Number of major customers accounting for 100% of annual sales			4
Number of major vendors accounting for 100% of pigment purchases			1	1
Number of major vendors accounting for 100% of canisters purchases			1	1
Number of major customers accounting for 100% of accounts receivable			2
One Customer [Member] | Revenues [Member]
Concentration risk, percentage	90.00%	93.00%
One Customer [Member] | Accounts Receivable [Member]
Concentration risk, percentage		20.00%
One Customer [Member] | Accounts Receivable [Member]
Concentration risk, percentage		76.00%

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - shares

Mar. 20, 2019

Nov. 30, 2018

Nov. 18, 2018

Dec. 31, 2019

Nov. 30, 2019

Oct. 31, 2019

Mar. 31, 2019

Mar. 31, 2019

Jan. 31, 2019

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Dec. 31, 2017

Subsequent Event [Line Items]

Number of shares granted

600,000

600,000

19,950,000

Series A Convertible Preferred Stock [Member]

Subsequent Event [Line Items]

Conversion of stock, shares converted (in shares)

6,095,569

400,000

20,000

73,000

Conversion of shares of preferred stock to common stock (in shares)

(304,778)

(20,000)

20,000

(73,000)

Restricted stock awards issued

Subsequent Event [Member] | Restricted Stock [Member] | Investor Relation Services [Member]

Subsequent Event [Line Items]

Restricted stock awards issued

280,000

33,333

Subsequent Event [Member] | Three Director [Member]

Subsequent Event [Line Items]

Vesting period

1 year

Subsequent Event [Member] | Three Director [Member] | Restricted Stock [Member]

Subsequent Event [Line Items]

Number of shares granted

240,000

Subsequent Event [Member] | Three Director [Member] | Restricted Stock Units (RSUs) [Member]

Subsequent Event [Line Items]

Number of shares granted

240,000

Subsequent Event [Member] | Dr. Arthur Laffer [Member]

Subsequent Event [Line Items]

Vesting period

1 year

Subsequent Event [Member] | Dr. Arthur Laffer [Member] | Restricted Stock [Member]

Subsequent Event [Line Items]

Number of shares granted

240,000

Subsequent Event [Member] | Director [Member] | Restricted Stock [Member]

Subsequent Event [Line Items]

Restricted stock awards issued

240,000

Subsequent Event [Member] | Series A Convertible Preferred Stock [Member]

Subsequent Event [Line Items]

Conversion of stock, shares converted (in shares)

20,000

20,000

Conversion of shares of preferred stock to common stock (in shares)

400,000

400,000